<SEC-DOCUMENT>0001144204-14-039077.txt : 20140626
<SEC-HEADER>0001144204-14-039077.hdr.sgml : 20140626
<ACCEPTANCE-DATETIME>20140623170127
ACCESSION NUMBER:		0001144204-14-039077
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20131231
FILED AS OF DATE:		20140623
DATE AS OF CHANGE:		20140623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMERICAN SHARED HOSPITAL SERVICES
		CENTRAL INDEX KEY:			0000744825
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				942918118
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08789
		FILM NUMBER:		14935667

	BUSINESS ADDRESS:	
		STREET 1:		FOUR EMBARCADERO CENTER
		STREET 2:		SUITE 3700
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111-4107
		BUSINESS PHONE:		415-788-5300

	MAIL ADDRESS:	
		STREET 1:		FOUR EMBARCADERO CENTER
		STREET 2:		SUITE 3700
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111-4107
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>v382020_10ka.htm
<DESCRIPTION>FORM 10-K/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-K/A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amendment No. 1 <B> (Mark One)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Wingdings"><B>x</B></FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Annual Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act of 1934</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>For The Fiscal Year Ended December 31, 2013</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Wingdings"><B>&uml;</B></FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Transition Report Pursuant To Section 13
or 15(d) Of The Securities Exchange Act of 1934 </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>For The Transition Period From _______________ to _______________ .</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number 1-08789</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">American Shared Hospital Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; text-align: center"><FONT STYLE="font-size: 10pt"><B>California</B></FONT></TD>
    <TD STYLE="width: 45%; text-align: center"><FONT STYLE="font-size: 10pt"><B>94-2918118</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction of</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>incorporation or organization)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Four Embarcadero Center, Suite 3700, San Francisco, California</B></FONT></TD>
    <TD STYLE="width: 42%; text-align: center"><FONT STYLE="font-size: 10pt"><B>94111-4107</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of Principal Executive Offices)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number,
including area code: (415) 788-5300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Title of each class</U></B></FONT></TD>
    <TD STYLE="width: 50%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Name of each exchange on which registered</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Stock No Par Value</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>NYSE MKT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#9;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section
12(g) of the Act: None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-size: 10pt">
No </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-size: 10pt">
No </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-size: 10pt">
No </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-size: 10pt">
No </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of &ldquo;large accelerated
filer&rdquo;, &ldquo;accelerated filer&rdquo;, and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act (check
one):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">Large accelerated filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">Accelerated Filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">Non-accelerated Filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">Smaller reporting company <FONT STYLE="font-family: Wingdings">x</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is a shell company
(as defined in Rule 12b-2 of the Act). Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT> No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2013, the aggregate market
value of the common stock held by non-affiliates of the registrant was approximately $7,342,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of common stock of the
registrant outstanding as of March 1, 2014: 4,608,870.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE &mdash; EXHIBIT FILING
ONLY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">American Shared Hospital Services (the &ldquo;Company&rdquo;)
is filing this Amendment No.&nbsp;1 (this &ldquo;Amendment&rdquo;) to its Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2013 (the &ldquo;Form 10-K&rdquo;), originally filed on March&nbsp;31, 2014. This Amendment is an exhibit-only
filing in response to comments received from the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) regarding a
request for confidential treatment of certain portions of Exhibit 10.22B originally filed with the Form 10-K. This Amendment is
being filed solely to re-file Exhibit 10.22B based on Commission comments. In addition, as required by Rule 12b-15 under the Securities
Exchange Act of 1934, as amended, new certifications by our principal executive officer and principal financial officer are filed
as exhibits to this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment is limited in scope to the items identified above
and should be read in conjunction with the Form 10-K. This Amendment does not reflect events occurring after the filing of the
Form 10-K and no revisions are being made to the Company&rsquo;s financial statements pursuant to this Amendment. Other than the
filing of the information identified above, this Amendment does not modify or update the disclosure in the Form 10-K in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM&nbsp;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 89%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">10.22b</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Lease Agreement for a Gamma Knife Unit (Perfexion Upgrade) effective July 30, 2013 between GK Financing, LLC and Tufts Medical Center, Inc. (Confidential material appearing in this document has been omitted and filed separately with the Securities and Exchange Commission in accordance with Rule 24b-2, promulgated under the Securities and Exchange Act of 1934, as amended. Omitted information has been replaced with asterisks.)</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">31a</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Rule 13a-14(a)/15d-14(a) Certifications</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">31b</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Rule 13a-14(a)/15d-14(a) Certifications</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of Section&nbsp;13
or 15(d)&nbsp;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Dated: June&nbsp;23, 2014 &nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">American Shared Hospital Services</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 51%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 45%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.75pt solid">/s/ Ernest
        A. Bates, M.D.</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Ernest A. Bates</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><I>Chairman of the Board and<BR>
 Chief Executive Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22B
<SEQUENCE>2
<FILENAME>v382020_ex10-22b.htm
<DESCRIPTION>EXHIBIT 10.22B
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.22b</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Confidential material appearing in this document
has been omitted and filed separately with the Securities and Exchange Commission in accordance with Rule 24b-2, promulgated under
the Securities and Exchange Act of 1934, as amended. Omitted information has been replaced with asterisks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>LEASE AGREEMENT FOR A GAMMA KNIFE
UNIT </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(PERFEXION UPGRADE)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.5in">This LEASE
AGREEMENT FOR A GAMMA KNIFE UNIT (PERFEXION UPGRADE) (this &quot;Agreement&quot;) is dated effective July 30, 2013 (the &quot;Effective
Date&quot;), and is entered into by and between TUFTS MEDICAL CENTER, INC., a not-for-profit Massachusetts corporation (formerly
known as New England Medical Center Hospitals, Inc.) (&quot;Medical Center&quot;), and GK FINANCING, LLC, a California limited
liability company (&quot;GKF&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Recitals:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.55in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GKF
and Medical Center entered into a Lease Agreement for a Gamma Knife Unit dated October 5, 1998, which was amended by a certain
Addendum to Lease Agreement for a Gamma Knife Unit dated effective April 1, 2005 (collectively, the &quot;Prior Lease&quot;). Pursuant
to the Lease, GKF is leasing to Medical Center a Leksell Stereotactic Gamma Knife unit, Model 4C (the &ldquo;Model 4C&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.55in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February 28, 2008, Medical Center changed its name from New England Medical Center Hospitals, Inc. to Tufts Medical Center, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.55in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
parties intend to upgrade the Model 4C to a Leksell Gamma Knife Perfexion which will be equipped with new cobalt-60 (the &quot;Equipment&quot;
or &quot;Perfexion&quot;) which will be leased by GKF to Medical Center pursuant to the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Agreement:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.55in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify; text-indent: 0.55in"><B>NOW,
THEREFORE</B>, in consideration of the mutual covenants and agreements set forth herein, and for other good and <FONT STYLE="font-size: 10pt">valuable</FONT>
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lease</U>.
Subject to and in accordance with the covenants and conditions set forth in this Agreement, GKF hereby leases to Medical Center,
and Medical Center hereby leases from GKF, the Equipment. The Equipment to be leased to Medical Center pursuant to this Agreement
shall include the latest approved Gamma Knife technology available as of the date of this Agreement, including all hardware and
software related thereto as listed in the Specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution
of LGK Agreement by and between Medical Center and Elekta</U>. Medical Center agrees that simultaneously with the execution of
this Agreement it shall execute that certain LGK Agreement with Elekta, (hereinafter referred to as the &quot;LGK Agreement&quot;),
a copy of which is attached hereto as Exhibit 1 and incorporated herein by this reference. GKF hereby grants to Medical Center
a non-exclusive right and sublicense to use the &quot;LGP Software&quot; as defined in and contemplated under, and subject to the
terms and conditions of, the LGK Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Perfexion
Upgrade</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions set forth below, GKF, at GKF's cost and expense, shall upgrade the Model 4C to the Equipment described
in Recital C above (the &quot;Perfexion Upgrade&quot;). GKF shall be responsible for all third party costs related to installation
and rigging associated with the Perfexion and de-installation of the Model 4C. In connection with the Perfexion Upgrade, GKF shall
also upgrade the flooring and painting in the Medical Center gamma knife suite. In connection with the Perfexion Upgrade, Medical
Center, at Medical Center's cost and expense, shall provide GKF with Medical Center personnel (including Medical Center physicists)
and services upon request and as required by GKF, among other things, to oversee, supervise and assist with construction and compliance
with local, state and federal regulatory requirements and with nuclear regulatory compliance issues and the calibration of the
Perfexion, and modification of the Determination of Need, as necessary. Subject to Medical Center's compliance with Section 3.2
below, GKF shall use commercially reasonable efforts to perform the Perfexion Upgrade in the Fall of 2013. The Parties agree that,
once the Model 4C is no longer operable due to the commencement of de-installation, GKF will use commercially reasonable efforts
to complete the installation and rigging of the Perfexion within six (6) weeks (the &ldquo;Down Period&rdquo;) so as to minimize
the interruption of Medical Center&rsquo;s services to its patients. GKF will provide Medical Center with not less than sixty (60)
days notice of the approximate dates of the Down Period so that Medical Center can appropriately manage patient scheduling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, the Perfexion Upgrade shall be performed by GKF only after all licenses, permits, approvals, consents and authorizations
necessary and appropriate for the Perfexion Upgrade, including, without limitation, the proper handling of the cobalt-60 (collectively,
the &quot;Permits&quot;), have been obtained by Medical Center at Medical Center's sole cost and expense (other than any filing
or registration fees which shall be paid for by GKF). The timing and procedure for such Perfexion Upgrade shall be as mutually
agreed upon between the parties. Medical Center represents and warrants to GKF that the Site and shielding in the vault for the
Perfexion are compliant with all applicable Nuclear Regulatory Commission and other federal and state requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GKF
confirms and warrants that the Perfexion fits into the existing footprint of the Model 4C, that there is no need for construction
at the site (other than minor modifications to be made by GKF as needed), and that Medical Center&rsquo;s site meets all requirements
of the Site Planning Criteria, as that term is used in the purchase agreement between Elekta, Inc. and GKF; provided that, in so
warranting, GKF relies upon the warranties and representations made by Medical Center under the Prior Lease and in this Agreement,
including without limitation, Section 3.2 above (all of which representations and warranties shall survive and remain in full force
and effect).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical
Center warrants that it shall utilize its best efforts to fulfill on an expeditious basis its obligations under this Section 3.
Medical Center further warrants that it shall on a regular basis keep GKF informed of Medical Center's progress in fulfilling its
obligations pursuant to this Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
receipt of Elekta&rsquo;s report on the results of the Acceptance Tests (as defined in the LGK Agreement), Medical Center shall
have three (3) business days to review and validate the results of the Acceptance Tests to confirm that the Perfexion meets the
manufacturer&rsquo;s specifications and documentation. If Medical Center fails to respond within such three (3) business day period,
Medical Center shall be deemed to have validated and confirmed the results of the Acceptance Tests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is understood by the parties that GKF is not responsible for any additional upgrades, hardware, cobalt reloading, software changes
and/or other modifications to the Perfexion except as expressly set forth herein or otherwise agreed upon in writing by Medical
Center and GKF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
Medical Center notifies GKF at least one hundred eighty (180) days prior to the expiration of the Term that Medical Center wishes
to further extend the Term of its Lease Agreement with GKF upon such terms as shall be mutually agreed upon in writing between
the parties, GKF shall remove the Perfexion, at its sole expense, within ninety (90) days after the expiration of the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary set forth in this Agreement, (i) GKF shall de-install, remove and retain all ownership rights and title
to the existing Model 4C; (ii) GKF shall acquire and hold title to the Perfexion; and (iii) Medical Center shall have no ownership
interest (or option to purchase any ownership interest) in the Model 4C and/or the Perfexion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the date on which the Model 4C is no longer operable due to the commencement of its de-installation (the &ldquo;Early Termination
Date&rdquo;), the Prior Lease shall be terminated and of no further force and effect; provided, however, that those provisions
of the Prior Lease that are expressly stated or intended to survive termination of the Prior Lease shall survive and remain applicable
beyond the Early Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Services of GKF</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GKF
shall provide maintenance and service of the Equipment as needed for the term of this Agreement to keep the Equipment in a good
state of repair, reasonable wear and tear excepted, including but not limited to providing a minimum of two PMI (Preventative Maintenance
Inspections) per year and repair work as needed. GKF agrees to exercise due and proper care in the repair and maintenance of the
Equipment. GKF shall have the right of access to the Equipment for the purpose of inspecting same at all reasonable times and upon
reasonable notice. In the event the Equipment is improperly used by Medical Center or its employees, agents, officers and physicians,
GKF may service or repair the same as needed and such expense shall be paid by Medical Center, unless the repair is covered by
the Repair Service Agreement, if any, referenced in Section 17, below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
of the calibration phantom system by the Medical Center as requested by the Medical Center, based on availability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Training
of Medical Center staff on the proper use of the Equipment (i) at the time of installation of the Perfexion and (ii) at the request
of Medical Center for the term of this Agreement, such requests not to exceed more than one request annually;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the termination of this Agreement, the de-installation and removal of the Perfexion, including any third party costs (but excluding
Medical Center costs). Medical Center, at Medical Center's cost and expense, shall provide GKF with Medical Center personnel (including
Medical Center physicists) and services upon request and as required by GKF to oversee, supervise and assist with such de-installation
and removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally
omitted.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term
of the Agreement</U>. The initial term of this Agreement (the &quot;Term&quot;) shall commence as of the Effective Date and, unless
earlier terminated or extended in accordance with the provisions of this Agreement, shall continue until the date that is six (6)
years after the date on which the first procedure using the Perfexion is performed at the Site (the &quot;First Procedure Date&quot;).
Medical Center's obligation to make the rental payments to GKF for the Equipment as described in Paragraph 7 below shall commence
on the first day of the first full month after the Effective Date of this Agreement. The rental payments described in Paragraph
7 shall apply to the Model 4C until such time as it is upgrade to the Perfexion, and shall then continue to apply to the Perfexion
for the duration of the Term of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Per
Procedure Payments</U>. Medical Center shall pay to GKF the applicable per procedure payment as specified in Exhibit 2 for the
use of the Equipment, subject to adjustment as set forth in Sections 7.1(a) and 7.1(b) below. A &quot;procedure&quot; shall be
defined as a single patient treatment session using the Equipment provided by GKF pursuant to this Agreement, that may include
one or more isocenters during that session. Medical Center shall be billed on the fifteenth (15th) and the last day of each month
for the actual number of procedures performed during the first and second half of the month, respectively. Medical Center shall
pay for the procedures invoiced within thirty (30) days after being invoiced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The parties acknowledge
that the compensation payable by Medical Center for the Perfexion as set forth in this Agreement has been negotiated by the parties
at arm&rsquo;s length based upon reasonable and jointly derived assumptions regarding the capacity for clinical services available
from the Perfexion, Medical Center&rsquo;s capabilities in providing high quality radiation oncology services, market dynamics,
GKF&rsquo;s risk in providing the Perfexion, and the provision to GKF of a reasonable rate of return on its investment in support
of the Perfexion. Based thereon, the parties believe that the rent payments represent fair market value for the use of the Perfexion,
the de-installation and removal of the Model 4C, the Perfexion upgrade, maintenance and service, personal property taxes, cost
of insurance coverage for the Perfexion, and any other additional services and costs to be provided or paid for by GKF pursuant
to this Agreement. Medical Center undertakes no obligation to perform any minimum number of procedures on the Perfexion, and the
use of the Perfexion for the performance of procedures is wholly based upon the independent judgment of physicians who order such
procedures to meet the medical needs of their patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any time or from time-to-time after the Effective Date, the Medical Center&rsquo;s Commercial Rate with any &quot;Designated
Payor&quot; (excluding those covered in 7(b) below), is increased or decreased such that the new Commercial Rate for such Designated
Payor is greater or less than the &quot;Base Commercial Rate&quot; for that Designated Payor (or the then current Commercial Rate
if the Non-Medicare Fee Per Procedure rates shown in Exhibit 2 for such Designated Payor have previously been revised pursuant
to this subsection) by *, then, (1) Medical Center shall notify GKF thereof in writing (but without disclosing the identity of
the Designated Payor) within thirty (30) days of any such increase or decrease and shall provide GKF with reasonably sufficient
documentation evidencing the revised Commercial Rate for that Designated Payor (and the amount of the increase or decrease), including,
without limitation, copies of the applicable contractual language or fee schedule (with the identity of the Designated Payor redacted),
and any remittance advices, EOBs or other documentation showing the payments made to Medical Center by such Designated Payor immediately
before and after the subject increase or decrease to its Commercial Rate, it being understood that such documentation may become
available following the effective date of such increase or decrease and that Medical Center shall provide such documentation to
GKF as and when available; (2) effective in the next billing cycle after said notification (provided that such increase or decrease
to the Commercial Rate is then effective), the fee for procedures performed on patients who are assigned to or enrolled with such
Designated Payor shall be equal to the Non-Medicare Fee Per Procedure rates as shown in Exhibit 2 (or the then current Non-Medicare
Fee Per Procedure rates for such Designated Payor if said Non-Medicare Fee Per Procedure rates have previously been revised pursuant
to this subsection), increased or decreased therein by * of the dollar-for-dollar increase or decrease to the Commercial Rate for
that Designated Payor; and (3) the Non-Medicare Fee Per Procedure rates set forth in Exhibit 2 for all other Designated Payors
shall remain unchanged and in full force and effect. For example, if a Designated Payor&rsquo;s Commercial Rate decreases by *
from the Base Commercial Rate (which, for purposes of this example, is assumed to exceed the * threshold above), then, each Non-Medicare
Fee Per Procedure rate shown in Exhibit 2 for that Designated Payor shall be decreased by *.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any time or from time-to-time after the Effective Date, the &quot;Medicare Rate&quot; is increased or decreased such that the
new Medicare Rate is greater or less than the &quot;Base Medicare Rate&quot; (or the then current Medicare rate if the Medicare
Fee Per Procedure rates shown in Exhibit 2 have previously been revised pursuant to this subsection) by * or more, then, (1) Medical
Center shall notify GKF thereof in writing within thirty (30) days of any such increase or decrease and shall provide GKF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with
reasonably sufficient documentation evidencing the revised Medicare Rate (and the amount of the increase or decrease), including,
without limitation, copies of the applicable contractual language or fee schedule (with the identity of the Designated Payor redacted),
and any remittance advices, EOBs or other documentation showing the payments made to Medical Center immediately before and after
the subject increase or decrease to its Medicare Rate, it being understood that such documentation may become available following
the effective date of such increase or decrease and that Medical Center shall provide such documentation to GKF as and when available;
(2) effective in the next billing cycle after said notification (provided that such increase or decrease to the revised Medicare
Rate is then effective), the fee for procedures performed on Medicare patients shall be equal to the Medicare Fee Per Procedure
rates as shown in Exhibit 2 (or the then current Medicare Fee Per Procedure rates if said Medicare Fee Per Procedure rates have
previously been revised pursuant to this subsection), increased or decreased therein by * of the dollar-for-dollar increase or
decrease to the Medicare Rate. For example, if the Medicare Rate increases by * over the Base Medicare Rate (which, for purposes
of this example, is assumed to exceed the * threshold above), then, each Medicare Fee Per Procedure rate shown in Exhibit 2 shall
be increased by *.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary set forth in this Agreement, and in addition to GKF's termination rights set forth in Section 18 below,
GKF shall have the right in its sole and absolute discretion to terminate this Agreement upon ninety (90) days prior written notice
to Medical Center if, as a result of any actual or impending decrease to the Commercial Rates and/or the Medicare Rates, GKF projects
that the sum of all per procedure payments made by Medical Center to GKF under this Agreement during the next succeeding twelve
(12) month period will fall short of $750,000 in the aggregate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
used herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&quot;<U>Base
Commercial Rate</U>&quot; shall mean the Medical Center&rsquo;s Commercial Rate for the applicable Designated Payor (excluding
Medicare) as of the Effective Date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&quot;<U>Base
Medicare Rate</U>&quot; shall mean the Medical Center&rsquo;s Medicare Rate as of the Effective Date of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&quot;<U>Commercial
Rate</U>&quot; shall mean Medical Center's contracted reimbursement rate then in effect with a Designated Payor for the technical
component of all services (including, but not limited to, treatment planning and delivery, but excluding codes specifically related
to physics support) related to a procedure performed on the Equipment, including, without limitation, all adjustments and other
amounts payable to, or entitled to be collected by, Medical Center or its representatives or affiliates from such Designated Payor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&quot;<U>Designated
Payor</U>&quot; shall mean the payors listed on Exhibit 3 attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&quot;<U>Medicare
Rate</U>&quot; shall mean the aggregate Medicare fee-for-service reimbursement rate for the technical component of all services
(including, but not limited to, treatment planning and delivery, but excluding codes specifically related to physics support) related
to a procedure performed on the Equipment using CPT code 77371, defined as Stereotactic Radiosurgery Gamma, or any substitutions,
replacements and/or supplements thereto (or, if no longer in effect, their respective outpatient rate replacements for Gamma Knife
procedures), taking into account, without limitation, any and all new codes, repeals, modifications, changes in interpretation
and other adjusting factors, which reimbursement rates are payable to, or entitled to be collected by, Medical Center or its representatives
or affiliates from any and all Medicare-related payor sources, including, without limitation, carriers, fiscal intermediaries and
any other Medicare-related third party payors. Medical Center represents and warrants to GKF that the difference between the Medicare
Rate in effect immediately prior to the Effective Date and the Medicare Rate in effect as of the Effective Date is approximately
$4,600.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of the Equipment</U>. The Equipment may be used by Medical Center only at the Site and shall not be removed therefrom. Medical
Center shall not assign or sublease the Equipment or its rights hereunder without the prior written consent of GKF; which consent
shall not be unreasonably withheld. No permitted assignment or sublease shall relieve Medical Center of any of its obligations
hereunder. Medical Center shall not use nor permit the Equipment to be used in any manner nor for any purpose for which, in the
reasonable opinion of Elekta or GKF based on current medical practice, the Equipment is not designed or reasonably suitable. Medical
Center shall not permit any liens, whether voluntary or involuntary, to attach to the Equipment, without the prior written consent
of GKF. Medical Center shall have no interest in the Equipment other than the rights acquired as a lessee hereunder and the Equipment
shall remain the property of GKF regardless of the manner in which it may be installed or attached at the Site. Medical Center
shall, at GKF's request, affix to the Equipment tags, decals, or plates furnished by GKF, indicating GKF's ownership of the Equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Covenants of Medical Center</U>. In addition to the other covenants made by Medical Center, Medical Center shall at its own cost
and expense:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provide
properly trained professional, technical and support personnel and supplies required for the timely scheduling and treatment of
patients utilizing the Equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assume
all medical and financial responsibility for the overseers' monitoring of all patients' medical condition and treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fully
comply with all of its obligations under the LGK Agreement that affect the operation of the Equipment and/or that affect this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
request by GKF and at GKF&rsquo;s reasonable expense, Medical Center shall execute and deliver a commercially reasonable form of
consent to sublease, subordination or other documentation if such a document is reasonably requested by the third party financing
company which holds a security interest in the Perfexion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Covenants. Representations and Warranties of GKF</U>. In addition to the other covenants, representations and warranties, made
by GKF in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GKF
represents and warrants that GKF has full power and authority to enter into this Agreement, and that this Agreement does not and
will not violate any agreement, contract or instrument binding upon GKF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GKF
represents and warrants to Medical Center that, upon delivery of the Equipment to Medical Center, GKF shall use its best faith
efforts to require that Elekta meets its contractual obligations to GKF and puts the Equipment, as soon as possible, into good,
safe and serviceable condition and fit for its intended use in accordance with the manufacturer's specifications, guidelines and
field modification instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GKF
represents and warrants that throughout the term of this Agreement, Medical Center shall enjoy the use of the Equipment, free of
the rights of any other persons except for those rights reserved by GKF under this Agreement or granted to Elekta under the LGK
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
party shall indemnify, defend and hold harmless the other party, and such other party&rsquo;s directors, officers, employees, agents
and affiliates, from and against any and all claims, actions, liabilities, costs and expenses (including without limitation judgment
and settlement costs, court costs and attorneys&rsquo; fees) arising out of or relating to negligent or intentional acts or omissions
of the indemnifying party or any failure by the indemnifying party to perform any obligation or covenant of the indemnifying party
in this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical
Center shall further indemnify GKF for any damage to the Equipment to the extent such damage is caused by the negligent or willfully
wrongful acts or omissions of Medical Center or its agents, officers, physicians and employees and are not covered and reimbursed
by GKF&rsquo;s insurance. In the event the Equipment is destroyed or rendered unusable as a result of such negligent or willfully
wrongful acts or omissions, this indemnification shall extend up to (but not exceed) the full replacement value of the Equipment
at the time of its destruction less salvage value, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GKF
shall further indemnify Medical Center in the event that Medical Center suffers any loss, damage, claim or expense solely as the
result of GKF&rsquo;s breach of its obligations under Section 17, below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ownership/Title</U>.
It is expressly understood that Medical Center shall acquire no right, title or interest in or to the Equipment, other than the
right to the possession and use of the same in accordance with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">GKF may at its sole
discretion finance the Equipment. Financing may be in the form of an installment loan or a capitalized lease or other commercially
available debt instrument. Should GKF finance the Equipment through an installment loan, GKF shall be required to provide the Equipment
as collateral against the loan. Should GKF finance the Equipment through a capitalized lease title shall vest with the lessor until
GKF exercises its buy-out option. In addition, should GKF finance the Equipment, said agreement may be used as collateral against
the loan. No financing by GKF will relieve GKF of its obligations to Medical Center or materially change Medical Center's duties
or materially increase the burdens or risks imposed on Medical Center. Medical Center's interest under this Agreement shall be
subject and subordinate to the interests of the Lender, which Medical Center shall promptly confirm in writing on Lender's form,
if requested by GKF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cost
of Use of the Equipment</U>. Except as is otherwise provided herein, Medical Center shall bear the entire cost of using the Equipment
during the Term of this Agreement. This shall include, but not be limited to, providing trained professionals, technical and support
personnel and supplies to properly operate the Equipment. Medical Center shall be fully responsible and liable for all acts and/or
omissions of such professional, technical and support personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
GKF shall pay any personal property taxes levied against the Equipment and any other taxes or governmental fees or assessments,
however denoted, whether of the federal government, any state government or any local government, levied or based on this Agreement
or the use of the Equipment except for those taxes, if any, pertaining to the gross income or gross receipts of Medical Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally
omitted.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally
omitted.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Repair
Service Agreement</U>. GKF may at its discretion enter into a Repair Service Agreement with Elekta. If GKF has entered into a Repair
Service Agreement with Elekta, (a) GKF agrees to fulfill all of its obligations under the Repair Service Agreement and acknowledges
that Medical Center is a third party beneficiary of the Repair Service Agreement; (b) GKF will reasonably pursue any and all remedies
it may have against Elekta under the Repair Service Agreement, if any, to insure that the Equipment will be in conformity with
Elekta's warranties so that it is free from defects in design, materials, workmanship or manufacture which result in noncompliance
with the Specifications and/or Elekta's warranties to GKF; provided that, for the avoidance of doubt, none of the foregoing obligations
in this Section shall be binding upon GKF if GKF has not entered into a Repair Service Agreement with Elekta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
If, after the initial twenty-four (24) month period following the First Procedure Date or any subsequent 12 month period, the sum
of all per procedure payments made by Medical Center to GKF under this Agreement during the most recent twelve (12) month period
fell short of $750,000, then and in that event, GKF shall have the option (but not the obligation) of terminating this Agreement
upon the giving of written notice to Medical Center of said termination not less than one hundred and eighty (180) days prior to
GKF's designated termination date. GKF shall remove the Equipment, at its sole expense, within ninety (90) days after the designated
termination date, unless Medical Center notifies GKF within ninety (90) days following receipt of GKF's notice of termination that
it wishes to purchase the Equipment in cash at a price to be mutually agreed upon by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Option
to Extend Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the end of the initial Term, Medical Center shall have the option to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Renegotiate
this Agreement for a five year renewal term, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terminate
this Agreement. If Medical Center terminates this Agreement at the end of the initial Term, Medical Center shall have the option
to purchase the Equipment in cash at a price to be mutually agreed upon by the parties. Medical Center shall exercise such option
by giving written notice to GKF not less than ninety (90) days prior to the expiration of the initial Term. If Medical Center does
not issue such notice, Medical Center shall be deemed to have elected not to exercise such option, and GKF shall remove the Equipment,
at its sole cost and expense, within ninety (90) days after the expiration of the initial Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Medical Center shall
exercise one (1) of the two (2) options referred to above by mailing an irrevocable written notice thereof to GKF at Four Embarcadero
Center, Suite 3700, San Francisco, California, 94111, by registered mail, postmarked on or before the end of the year immediately
preceding the expiration of the initial Term of this Agreement. Any such notice shall be sufficient if it states in substance that
Medical Center elects to exercise its option and states which of the two (2) options referred to above Medical Center is exercising.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Warranties by GKF with Respect to the Equipment</U>. GKF SUPPLIES THE EQUIPMENT &quot;AS IS&quot; AND NOT BEING THE MANUFACTURER
OF THE EQUIPMENT OR THE MANUFACTURER'S AGENT, MAKES NO WARRANTY OR REPRESENTATION, EITHER EXPRESSED OR IMPLIED, AS TO THE EQUIPMENT'S
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, DESIGN, CONDITION, DURABILITY, CAPACITY, MATERIAL OR WORKMANSHIP OR AS TO PATENT
INFRINGEMENT OR THE LIKE, it being agreed that all such risks as between GKF and Medical Center, shall be borne by Medical Center.
Medical Center agrees to look solely to the manufacturer (Elekta) or to suppliers of the Equipment (and its software) for any and
all warranty claims with respect to the Equipment. Any and all warranties made by Elekta to GKF will be in its good faith best
efforts enforced by GKF on behalf of Medical Center during the initial Term hereof and any renewal Terms. Medical Center agrees
that GKF shall not be responsible for the operation of the Equipment. GKF shall not be responsible for any direct or indirect consequential
loss or damage resulting from the installation, operation or use of the Equipment or otherwise. Medical Center expressly waives
any right to hold GKF liable hereunder for any claims, demands and liabilities arising out of or in connection with the design,
manufacture, possession or operation of the Equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Events
of Default by Medical Center and Remedies</U>. The occurrence of any one of the following shall constitute an Event of Default
by Medical Center hereunder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical
Center fails to pay any installment of semi-monthly procedure payments when due when such default continues for a period of thirty
(30) days after notice thereof from GKF or its assignee is given to Medical Center;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical
Center attempts to remove, sell, transfer, encumber, sublet or part with possession of the Equipment or any items thereof, except
as expressly permitted herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical
Center shall fail to observe or perform any of the other obligations required to be observed or performed by Medical Center hereunder
and such failure shall continue uncured for sixty (60) days after written notice thereof to Medical Center by GKF;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical
Center ceases doing business as a going concern, makes an assignment for the benefit of creditors, admits in writing its inability
to pay its debts as they become due, files a voluntary petition in bankruptcy, is adjudicated a bankrupt or an insolvent, files
a petition seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar arrangement
under any present or future statute, law or regulation or files an answer admitting the material allegations of a petition filed
against it in any such proceeding, consents to or acquiesces in the appointment of a trustee, receiver, or liquidator of it or
of all or any substantial part of its assets or properties, or it or its shareholders shall take any action looking to its dissolution
or liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
sixty (60) days after the commencement of any proceedings against Medical Center seeking reorganization, arrangement, readjustment,
liquidation, dissolution or similar relief under any present or future statute, law or regulation, such proceedings shall not have
been dismissed, or if within thirty (30) days after the appointment without Medical Center's consent or acquiescence of any trustee,
receiver or liquidator of it or of all or any substantial part of its assets and properties, such appointment shall not be vacated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Upon the occurrence of
an Event of Default by Medical Center, GKF may at its option do any or all of the following: (i) by written notice to Medical Center,
terminate this Agreement as to the Equipment in default, wherever situated, and for such purposes, enter upon the Site without
liability for so doing or GKF may cause Medical Center and Medical Center hereby agrees to return the Equipment to GKF at Medical
Center's sole cost and expense; and (ii) sell, dispose of, hold, use or lease the Equipment in default, as GKF in its sole discretion
may determine (and GKF shall not be obligated to give preference to the sale, lease or other disposition of the Equipment over
the sale, lease or other disposition of similar Equipment owned or leased by GKF). In any event, Medical Center shall, without
further demand, pay to GKF an amount equal to all sums due and payable for all periods up to and including the date on which GKF
had declared this Agreement to be in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Medical Center agrees
that GKF shall have no obligation to sell the Equipment. Medical Center shall in any event remain fully liable for reasonable damages
as provided by law for all costs and expenses incurred by GKF on account of such default, including but not limited to, all court
costs and reasonable attorneys' fees. The rights afforded GKF hereunder shall not be deemed to be exclusive, but shall be in addition
to any other rights or remedies provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Events
of Default by GKF and Remedies</U>. The occurrence of any one of the following shall constitute an Event of Default by GKF hereunder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GKF
shall fail to observe or perform any of the obligations required to be observed or performed by GKF hereunder and such failure
shall continue uncured for sixty (60) days after written notice thereof to GKF by Medical Center;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GKF
ceases doing business as a going concern, makes an assignment for the benefit of creditors, admits in writing its inability to
pay its debts as they become due, files a voluntary petition in bankruptcy, is adjudicated a bankrupt or an insolvent, files a
petition seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar arrangement
under any present or future statute, law or regulation or files an answer admitting the material allegations of a petition filed
against it in any such proceeding, consents to or acquiesces in the appointment of a trustee, receiver, or liquidator of it or
of all or any substantial part of its assets or properties, or it or its shareholders shall take any action looking to its dissolution
or liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
sixty (60) days after the commencement of any proceedings against GKF seeking reorganization, arrangement, readjustment, liquidation,
dissolution or similar relief under any present or future statute, law or regulation, such proceedings shall not have been dismissed,
or if within thirty (30) days after the appointment without GKF's consent or acquiescence of any trustee, receiver or liquidator
of it or of all or any substantial part of its assets and properties, such appointment shall not be vacated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Upon the occurrence of
an Event of Default by GKF, Medical Center may at its option do any or all of the following: (i) by written notice to GKF, terminate
this Agreement and, in such event, GKF shall remove the Equipment at GKF's sole cost and expense or, in the absence of removal
by GKF within ninety (90) days after a written request therefor, Medical Center may remove the Equipment with all due care and
store the Equipment at GKF's sole cost and expense, or (ii) purchase the Equipment in cash at a price to be mutually agreed upon
by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">GKF shall in any event
remain fully liable for reasonable damages as provided by law for all costs and expenses incurred by Medical Center on account
of such default, including but not limited to all court costs and reasonable attorney's fees. The rights afforded Medical Center
hereunder shall not be deemed to be exclusive, but shall be in addition to any other rights or remedies provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">23.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Term of this Agreement (and any successive terms) GKF shall, at its own cost and expense, keep in effect an all risk and hazard
insurance policy covering the Equipment. The all risk and hazard insurance policy shall be for an amount not less than the replacement
cost of the Equipment. During the Term of this Agreement, Medical Center shall, at its own cost and expense, keep in effect public
liability and professional liability insurance policies concerning the operation of the Equipment by Medical Center. Said policies
shall be in the amounts of not less than $1,000,000 per occurrence and $5,000,000 in aggregate per year. Medical Center and GKF,
their successors and assigns, shall be named as additional insureds and/or loss payees on the insurance policies maintained hereunder
by the other party. Evidence of such insurance coverages shall be furnished by both parties to the other party upon written request,
by no later than the Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">23.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Equipment is rendered unusable as a result of any physical damage to, or destruction of, the Equipment, Medical Center shall
give to GKF immediate notice. GKF shall determine, within thirty (30) days after the date of occurrence of such damage or destruction,
whether the Equipment can be repaired. In the event GKF determines that the Equipment cannot be repaired, GKF at its sole cost
and expense shall promptly replace the Equipment subject to availability and subject, further, to Medical Center's obligations
under Section 11.2 above. This Agreement shall continue in full force and effect as though such damage or destruction had not occurred.
In the event GKF determines that the Equipment can be repaired, GKF shall cause the Equipment to be promptly repaired at its sole
expense, subject, however, to Medical Center's obligations under Section 4.1 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any notices required under this Agreement shall be sent in writing and shall be deemed to have been duly given if delivered by
hand or mailed by certified or registered mail to the following addresses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">To GKF:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;GK
Financing, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">Craig K. Tagawa,
C.E.O.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">Four Embarcadero
Center, Suite 3700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">San Francisco,
CA 94111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">To Medical
Center: &nbsp;&nbsp;&nbsp;&#9;Tufts Medical Center, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">750 Washington
Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">NEMC 428</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">Boston, MA
02111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Or to such other addresses
as either party may specify for the reception of notice from time to time in writing to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration/Supersedure</U>.
This Agreement contains the full and entire Agreement between the parties hereto, and no oral or written understanding is of any
force or effect whatsoever unless expressly contained in a writing executed subsequent to the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waivers</U>.
To the extent that either party fails or chooses not to pursue any of its remedies under this Agreement or pursuant to applicable
law, such shall not prejudice such party's rights to pursue any of those remedies at any future time and shall not constitute a
waiver of such party's rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignments</U>.
This Agreement is binding upon and shall inure to the benefit of the permitted successors or assigns of the respective parties
hereto, except that neither party may assign its rights or obligations under this Agreement without the express written consent
of the other (which consent shall not be unreasonably withheld or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>.
This Agreement shall not be amended or altered in any manner unless such amendment or alteration is in a writing signed by both
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Record-Keeping
Requirements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">29.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical
Center and GKF shall generate such records and make such disclosures as may be required, from time to time, by the Medicare, Medicaid
and other third party payment programs with respect to this Agreement in order to meet all requirements for participation and payment
associated with such programs, including but not limited to the matters covered by Section 1861(v)(1)(I) of the Social Security
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">29.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purpose of compliance with Section 1861(v)(1)(I) of the Social Security Act, as amended, and any regulations promulgated pursuant
thereto, both parties agree to comply with the following statutory requirements (a) until the expiration of four (4) years after
the termination of this Agreement, both parties shall make available, upon written request to the Secretary of Health and Human
Services or, upon request, to the Comptroller General of the United States, or any of their duly authorized representatives, the
contract, and books, documents and records of such party that are necessary to certify the nature and extent of such costs, and
(b) if either party carries out any of the duties of the contract through a subcontract with a value or cost of $10,000 or more
over a twelve month period, with a related organization, such subcontract shall contain a clause to the effect that until the expiration
of four (4) years after the furnishing of such services pursuant to such subcontract, the related organization shall make available,
upon written request to the Secretary, or upon request to the Comptroller General, or any of their duly authorized representatives
the subcontract, and books, documents and records of such organization that are necessary to verify the nature and extent of such
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supplier
and Owner of Perfexion</U>. The parties hereto agree that, notwithstanding anything to the contrary set forth herein, the Lease
is and shall be treated and interpreted as a &quot;finance lease,&quot; as such term is defined in Article 2A of the Uniform Commercial
Code, that GKF shall be treated as a finance lessor who is entitled to the benefits and releases from liability accorded to a finance
lessor under Article 2A of the Uniform Commercial Code. In furtherance of the foregoing, Medical Center acknowledges that, before
signing this Agreement, GKF has informed Medical Center in writing (a) that Elekta is the entity supplying the Perfexion, (b) that
Medical Center is entitled (under Section 2A of the Uniform Commercial Code) to the promises and warranties, including those of
any third party, provided to GKF by Elekta which is the entity supplying the goods in connection with or as part of the contract
by which GKF acquired the Perfexion or the right to possession and use of the Perfexion, and (c) that Medical Center may communicate
with Elekta and receive an accurate and complete statement of those promises and warranties, including any disclaimers and limitations
of them or of remedies. Medical Center also acknowledges that Medical Center has selected Elekta to supply the Perfexion and has
directed GKF to acquire the Perfexion or the right to possession and use of the Perfexion from Elekta. Nothing herein shall be
construed to limit GKF&rsquo;s obligations and responsibilities under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">31.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous
Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">31.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
invalidity or unenforceability of any portion or provision of this Agreement shall not effect the validity or enforceability of
any other portion, nor shall either party's implied or express consent to the breach or waiver of any provision of this Agreement
constitute a waiver of such provision as to any subsequent breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">31.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of any claim or controversy arising hereunder, the prevailing party in such claim or controversy shall be entitled to
a reasonable attorneys' fee in addition to whatever other relief said party would be otherwise entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">31.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Force
Majeure</U>. Failure to perform by either party will be excused in the event of any delay or inability to perform its duties under
this Agreement directly or indirectly caused by conditions beyond its reasonable control including without limitation, fires, floods,
earthquakes, snow, ice, disasters, Acts of God, accidents, riots, wars, operation of law, strikes, governmental action or regulations,
shortages of labor, fuel, power, materials, manufacturer delays or transportation problems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">31.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement may be executed in separate counterparts, each of which when so executed and delivered shall be an original, but all
of which counterparts shall together constitute the same instrument. The captions and paragraph headings used herein are for convenience
only and shall not be used in construing or interpreting this Agreement. This Agreement constitutes the full and complete agreement
and understanding between the parties hereto concerning the subject matter hereof and shall supersede any and all prior written
and oral agreements with regard to such subject matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">31.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary set forth in this Agreement, nothing set forth in this Agreement shall limit, impair or otherwise affect
the respective rights, obligations and remedies of the parties under the Prior Lease, provided however that the pricing terms of
the Prior Lease shall be replaced by Section 7 and Exhibit 2 of this Agreement, and provided further that, subject to Section 3.9
above, the Prior Lease shall terminate on the date of the de-installation of the Model 4C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the parties have signed this Agreement on the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-decoration: none"><B><U>GKF</U></B>:</TD>
    <TD COLSPAN="2" STYLE="text-decoration: none"><B><U>Medical Center</U></B>:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">GK FINANCING, LLC</TD>
    <TD COLSPAN="2">TUFTS MEDICAL CENTER, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">By:</TD>
    <TD STYLE="width: 43%">/s/ Ernest A. Bates, MD</TD>
    <TD STYLE="width: 7%">By:</TD>
    <TD STYLE="width: 43%">/s/ Okey Agba</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Ernest A. Bates, MD</TD>
    <TD>Name:</TD>
    <TD>Okey Agba</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Policy Committee Member</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>
<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Exhibit 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>LGK AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tpg17.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prepared for</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TUFTS MEDICAL CENTER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>750 WASHINGTON ST STE 1012<BR>
BOSTON, MA 02111-1526</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">JUNE 28, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEKSELL GAMMA KNIFE&reg; END USER AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">THIS AGREEMENT is entered into as of the
1st day of July, 2012 by and between ELEKTA, INC., a corporation organized and existing under the laws of Georgia (hereinafter
referred to as &ldquo;Elekta&rdquo;), and Tufts Medical Center,. (hereinafter referred to as &ldquo;End User&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.6in; text-align: center; text-indent: -3.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.6in; text-align: center; text-indent: -3.6in">WITNESSETH:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Elekta has agreed to sell the &ldquo;Leksell
Gamma Knife&reg;&rdquo; system (hereinafter defined and referred to as the &ldquo;LGK&reg;&rdquo;) to GK Financing, LLC.. hereinafter
referred to as &ldquo;Buyer&rdquo;), and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Buyer has agreed to lease the LGK&reg;
to End User under separate agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Elekta and End User wish to enter
this Agreement for their mutual benefit;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW THEREFORE, in consideration of the mutual covenants and
obligations, warranties and indemnities herein contained and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>ARTICLE I. <U>DEFINED TERMS. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">The following words and terms shall have the meanings
set forth opposite them in this Article I:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>Acceptance Tests</U> are
those tests which demonstrate that the LGK&reg; meets the manufacturer&rsquo;s specification and which are defined in the Purchase
Agreement between Buyer and Elekta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>Charging</U> means all handling
of the Cobalt Supply at the Site and the installation of such Cobalt Supply in the LGK&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>Cobalt Supply</U> means the
supply of the Cobalt-60 sources to be installed in the LGK&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>Effective Date</U> is the
date of execution of this Agreement by the End User, as indicated in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>Hardware </U>shall mean that
computer hardware and related equipment described in the Specification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>Lease Agreement</U> shall
mean the Agreement between Buyer and End User pursuant to which Buyer shall lease the LGK&reg; to End User.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>LGK&reg; </U> is the device,
which is technically specified in Exhibit A hereto, to be sold, delivered, and installed by Elekta at the Site.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>LGP Software</U> means the
dose planning software for the LGK&reg;, which is described in the Specification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>Site</U> shall mean that
location described on the Exhibit B hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>Site Planning Criteria</U>
are the requirements which the Site must meet to properly accommodate the LGK&reg; and are defined in the Purchase Agreement between
Elekta and Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -13.7pt"><U>Specification</U> refers
to the technical standards with which the LGK&reg; shall comply, as described in Exhibit A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>ARTICLE II. <U>PERMITS </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.1 <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permits</B>. End User shall obtain
any license (the &ldquo;User License&rdquo;) from the Nuclear Regulatory Commission (or relevant state agency if the Site is located
in an &ldquo;Agreement State&rdquo;) authorizing it to take possession of the Cobalt Supply and shall obtain such other licenses,
permits, approvals, consents and authorizations which may be required by local governmental or other regulatory agencies for the
Site, its preparation, the charging of the LGK&reg; with its Cobalt Supply, the conduct of Acceptance Tests, and the use of the
LGK&reg;. End User shall not run, operate, or otherwise use the LGK&reg;, except for the purpose of conducting the Acceptance Tests,
until the Acceptance Tests have been successfully completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>ARTICLE III. <U>OPERATION AND TRAINING. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.1 <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operation. </B>End User warrants
and covenants that the LGK&reg; shall not be run, operated or otherwise used, except by and to qualified employees or physicians,
who are suitably skilled and experienced to use the LGK&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.2 <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technical Training. </B>Elekta shall
provide to four (4) persons on the End User&rsquo;s staff instruction relating to the technical operation and maintenance of the
LGK. Such instruction shall not exceed two consecutive days and will be provided on site by installation personnel at the time
of install.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3 <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Introductory Clinical Training. </B>Introductory
Clinical Training Program. Indications, Technique, Literature, etc. Length of training is 5 consecutive days. Up to four (4) training
spaces included (Tuition only). May be substituted for Technical/Applications training course at Elekta Sweden as noted on Exhibit
A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.4 <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Post Clinical Start Up Site Visit</B>.
Elekta shall provide a one-day site visit from one Clinical Applications representative. The visit must be arranged within 3-6
months post clinical start up. The commitment will expire thereafter unless documented alternate arrangements are made. The purpose
is to ensure the customer is comfortable using all features in the Leksell GammaPlan&reg; PFXTM software.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>LGK&reg; Software</B>. Elekta hereby
consents to Buyer&rsquo;s sublicense to End User of the LGK&reg; Software, to be utilized only for the purpose of planning dosages
of treatments to be performed with the LGK&reg;. A copy of the LGK&reg; Software License from Elekta to Buyer is attached hereto
as Exhibit D End User agrees that its sublicense to the LGK&reg; Software shall be subject to the terms and conditions of Exhibit
D hereto. End User agrees, in favor of Elekta, to perform the obligations assigned to Buyer in Exhibit D hereto. In the event the
sublicense of the LGK&reg; Software from</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Buyer to End User is terminated due to an act or omission of
Buyer and without fault of the End User, then End User shall have the right to obtain from Elekta a direct royalty-free license
to utilize the LGK&reg; Software on the terms and conditions described in Exhibit D hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-indent: -0.05in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-indent: -0.05in">3.6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Intellectual Property</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;End User hereby
acknowledges that the trademarks Gamma Knife&reg; and Leksell Gamma Knife&reg; (collectively, the &ldquo;Mark&rdquo;) are protected
by United States federal registrations and the Mark constitutes valuable intellectual property of an affiliate of Elekta in which
it has established substantial goodwill. End User hereby acknowledges that proper use of the Mark in any advertising of End User&rsquo;s
own surgical services performed with the LGK&reg; surgical instrument is highly important to maintaining such value and goodwill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the
terms and conditions of this section, Elekta, as agent for Elekta Instrument, S.A. of Geneva, Switzerland, the owner of the Mark,
hereby grants End-User a non-exclusive, royalty-free license without right to sublicense solely for the purpose of using the Mark
in connection with the promotion and advertising of any of End User&rsquo;s own services to be performed by use of the LGK&reg;
surgical instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;End User, in the conduct of End User&rsquo;s
business, is strictly prohibited from using the Mark in or as its official legal name. However, End User may use the trademark
as part of the following fictitious trade name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in">&ldquo;Gamma Knife&reg; Center of Tufts Medical Center&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.5pt">As long as End User
utilizes a fictitious trade name which includes the Mark, End User shall not perform radiosurgical services with any equipment
other than the LGK&reg;. If End User performs any radiosurgical service with any equipment other than the LGK&reg; or if End User
ceases to perform radiosurgical services with the LGK&reg;, End User shall immediately cease utilizing the Mark as part of its
fictitious trade name. Notwithstanding the foregoing, and for the avoidance of doubt, End User shall be entitled to use the Elekta
Axesse system to perform radiological services at Tufts Medical Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In advertising,
references to the Mark must include the registration symbol &reg; and such symbol must be used at least once per piece of advertising
material along with the words &ldquo;Gamma Knife&reg; and Leksell Gamma Knife&reg; are U.S. federally registered trademarks of
Elekta Instrument S.A.., Geneva, Switzerland&rdquo; somewhere in the advertisement. Elekta reserves the right to require End User
to discontinue the use of advertising that does not conform to such requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;End User may
use the words &ldquo;Gamma Knife&reg; Center of [<I>add distinctive name</I>]&rdquo; as part of any internet domain name, or URL,
telephone number or other communications address or symbol provided that the full name, &ldquo;Gamma Knife&reg; Center of [<I>add
distinctive name</I>]&rdquo; is used. User may use a variation or abbreviation of such term only after obtaining Elekta&rsquo;s
prior written consent to the proposed use in question. User may <U>not under any circumstances,</U> use the words &ldquo;gamma
Knife&reg; &rdquo; alone, for any internet domain name, or URL, telephone number or other communications address or symbol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All advertising or promotional materials
in which the mark is utilized shall comply with all applicable laws and regulations as well as the standards of proper advertising.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elekta shall have the right to terminate
the license granted in this section with immediate effect if End User violates any provision of this section or utilizes the Mark
in any manner which, in the sole opinion of Elekta, presents a reasonable possibility of damage to the Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon termination of the license granted
by this section, End User shall immediately cease all use of the mark, including, but not limited to, the use permitted under subsection
(e) of this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Buyer acknowledges
that a breach of any of its covenants or agreements hereunder will cause immediate and irreparable harm to Elekta and Elekta Instrument
S.A. End User acknowledges and agrees that no adequate remedy at law exists for any such breach, and End User agrees that in the
event of such a breach Elekta shall be entitled to injunctive relief and such other relief as any court with jurisdiction may deem
just and proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-indent: -0.05in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-indent: -0.05in"><B>ARTICLE IV. <U>CONFIDENTIALITY
</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;End User shall treat and maintain
as confidential all technical information and know-how to it pursuant to this Agreement (including LGK&reg; Software), except for
know-how specifically designated as non-confidential pursuant to this Agreement or otherwise so designated by the Elekta. End User
shall not disclose any aspect of such know-how (including the LGK&reg; Software) to any other Person, including any corporation
or governmental or quasi-governmental agency; provided that, End User shall have the right to disclose such know-how to its employees
and resident physicians to the extent necessary for use of the LGK&reg;, but End User shall be responsible to ensure that such
know-how is not disclosed by such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Article IV
shall survive the termination of this Agreement and shall apply with equal force to any technical information or know-how concerning
the LGK&reg; acquired by End User other than pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligations of confidentiality
and restriction of access pursuant to this Article IV shall not apply to any trade secret or confidential information that was
(a) in the public domain at the time of such access or subsequently came in to the public domain through no fault of the Person
subject to the provisions of Article IV; (b) rightfully known to the Person given such access prior to such access or developed
independently by the Person given such access; (c) received by the Person given such access as a matter of right from a source
other than a Person subject to the provisions of this Article IV; or (d) required to be disclosed by subpoena or court order, but
Buyer shall give immediate notice of such subpoena or court order to Elekta and shall request the court to grant confidential treatment
to the confidential information disclosed pursuant to such subpoena or court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: black 1pt solid"><B>ARTICLE V. WARRANTY AND REPAIR SERVICE
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elekta provides the warranty for the LGK&reg; set forth
in Exhibit C hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: black 1pt solid"><B>ARTICLE VI. EXCUSABLE DELAYS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the performance of this Agreement by
Elekta or Buyer or any obligation of Elekta or Buyer hereunder is prevented, restricted or interfered with by reason of fire, explosion,
acts of God, labor disputes or accidents affecting performance under this Agreement, or war, mobilization, civil commotions, blockade
or embargo, or any law, regulation, ordinance or requirement of any government or regulatory agency, or any other act whatsoever
similar to those above enumerated, or any other circumstance being beyond the reasonable control of Elekta or Buyer, then and in
that event Elekta or Buyer, as the case may be, shall promptly notify the other parties hereto of the resulting difficulties therefrom,
and any of the foregoing events shall excuse any performance required under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ARTICLE VII. <U>LIMITATION OF LIABILITY; INDEMNIFICATION.
</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The exclusive remedies of End User
and Elekta&rsquo;s sole liabilities for breaches of this Agreement shall be limited to those specifically provided for in Section
5.1 (and Exhibit E hereto) and in this Article VII. In no event shall Elekta be liable to End User for loss of use, revenue or
profit, or for any other direct, indirect, incidental or consequential damage, whether arising in contract or tort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elekta shall defend and indemnify
End User and its Affiliates, agents, servants and employees, and hold them harmless from and against all damages, claims, judgments
and liabilities by or to third parties (plus litigation costs incurred) resulting from injury to or death of any person or physical
loss or damage to property arising out of defective materials, workmanship, or manufacture of the LGK&reg; or the defective maintenance
of the LGK&reg; (but, with respect to maintenance, only to the extent performed by or on behalf of Elekta).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;End User shall defend and indemnify
Elekta and its Affiliates, agents, servants, and employees and hold them harmless from and against all damages, claims, judgments
and liabilities by or to third parties (plus litigation costs incurred) resulting from injury to or death of any person or physical
loss or damage to property arising out of the operation or medical use or misuse of the LGK&reg; by or for End User (but which
is not attributable to defective materials, workmanship or manufacture of the LGK&reg;), the defective maintenance of the LGK&reg;
by or for End User (but only to the extent not performed by or on behalf of the Elekta), the failure of the Site to comply with
the Site Planning Criteria, or the training provided by Elekta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-indent: -0.05in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-indent: -0.05in"><B>ARTICLE VIII. <U>MISCELLANEOUS
PROVISIONS.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment. </B>No party hereto
shall assign its respective rights or obligations under this Agreement (including the LGP Software License) in whole or in part
to any person without the prior written consent of the other party, except as provided in this Section 8.2 hereinafter. In the
event of any assignment or transfer by End User of its rights or duties under this Agreement or the Lease or of any sale, transfer,
lease or sublease of the LGK&reg; or any component thereof to a third party, End User shall obtain the prior approval of Elekta
of the proposed transferee (such approval not to be unreasonably withheld) and cause such transferee, prior to such transfer, to
sign (1) an agreement that any acquired interest in the LGK&reg; System is subject to the terms and conditions of this Agreement
and evidencing such transferee&rsquo;s agreement to be bound, to the same extent as End User, by the then-surviving provisions
of this Agreement, including but not limited to the technical and scientific information provisions (Section 3.3), the confidentiality
provisions (Article IV), the provisions of Articles V and VII hereof, and the provisions of the LGK&reg; Software License or (2)
a similar agreement otherwise approved by the Elekta, which approval shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Subcontractors</B>. Elekta
shall be entitled to appoint subcontractors or any other third parties for the performance or fulfillment in whole or in part of
Elekta&rsquo;s obligations under this Agreement without the consent of End User, and Elekta shall be fully responsible and liable
for the performance of other entities. Elekta shall be entitled to assign any of its rights or obligations hereunder to any of
its Affiliates without the consent of End User, but Elekta agrees that it will be fully responsible for any obligations assigned
to Elekta&rsquo;s Affiliates hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Arbitration. </B>All disputes
arising in connection with this Agreement shall be finally resolved by arbitration in Atlanta, Georgia under the Commercial Arbitration
Rules of the American Arbitration Association. Judgment upon the award rendered may be entered in any court having jurisdiction
or application may be made to such court for judicial acceptance of such award and an order of enforcement as the case may be.
The parties hereby agree the rendering of an award by the arbitrator or arbitrators shall be a condition precedent to the initiation
of any legal proceeding with respect to any dispute arising in connection with this Agreement. This Agreement shall be governed
by and construed in accordance with the laws of the State of Georgia and the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement</B>. This Agreement
constitutes the entire agreement between the parties hereto and supersedes any prior or contemporaneous agreements, negotiations
or discussions between the parties with respect to the subject matter hereof. No amendment of the provisions of this Agreement
will be valid unless made in writing and signed by both parties hereto..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IN WITNESS WHEREOF, <FONT STYLE="font-size: 10pt">the parties
hereto have signed this Agreement in duplicate as of the date first written above.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD COLSPAN="2"><B>ELEKTA INC.</B></td>
    <td>&nbsp;</td>
    <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif"><b>END USER</b></font></td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 8%"><font style="font: 10pt Times New Roman, Times, Serif"><b>By: </b></font></td>
    <td style="width: 39%"><font style="font: 10pt Times New Roman, Times, Serif"><b>/s/ Ian Dickson</b></font></td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 7%"><font style="font: 10pt Times New Roman, Times, Serif"><b>By: </b></font></td>
    <td style="width: 43%; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>/s/ Denise Schepici</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="border-top: Black 1pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Title:&nbsp;&nbsp;</b></font></td>
    <td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Treasurer</b></font></td>
    <td>&nbsp;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Title: </b></font></td>
    <td style="border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Sr. Vice President</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Date: </b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>11/6/13</b></font></td>
    <td>&nbsp;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Date: </b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>8/1/13</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPECIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leksell Gamma Knife &reg; PERFEXION&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; border-bottom: Black 2.5pt double">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PRODUCT SPECIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Standard turn-key system</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 7%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Qty</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 65%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Description</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 26%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Article no.</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Leksell Gamma Knife<SUP>&reg;</SUP> PERFEXIONTM</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">715000</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">2</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Leksell<SUP>&reg;</SUP> Coordinate FrameTM Kit for PERFEXIONTM</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1002407</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Leksell GammaPlan<SUP>&reg;</SUP></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">in BOM</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">PERFEXION<SUP>TM</SUP> system tool kit</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LSS Spare Part Kit for Leksell<SUP>&reg;</SUP> Coordinate FrameTM</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">1002406</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Skull scaling instrument</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">A0202-01</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">CT planning kit</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">MRI planning kit</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">X-ray planning kit</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Set of Co<SUP>60</SUP> sources</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">2000000</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Cobalt loading</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Site planning</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Installation and commissioning</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Support and Education &amp; Training for PERFEXIONTM</FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 14.15pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">SER PERFEXION</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">0001</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="text-align: center; padding-right: 9pt; padding-left: 9pt; font-size: 12pt"></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Leksell Gamma Knife<SUP>&reg;</SUP> PERFEXION&trade; </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Radiation unit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- With radiation shielding doors and collimator system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Patient Positioning SystemTM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- Patient couch and automatic Patient Positioning
System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Covers for radiation unit and Patient Positioning
System</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Electric cabinet</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- Electric cabinet with cabling</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- ECU - central unit and safety system electronic
board, circuit breakers and cabling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- SDU - sector drive electronic board, circuit breakers
and cabling</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">- PPC1-software</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">- PPC2- software</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">- Medical UPS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Operator area</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- Office cabinet</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- Keyboard and mouse</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- Operator console with patient and operator audio/video,
power supply, opto insulators, cabling and connectors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Flat screen monitors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Office UPS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">MCU kit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">MCU PC with USB CAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">MCU software</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Treatment couch</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Height adjustable mattress</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Manual controls for treatment setup</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Frame adapter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Model &ldquo;Standard G&rdquo;. For interfacing between
Leksell Coordinate Frame model G and Leksell Gamma Knife PERFEXION&trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Clearance check tool</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Document set</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Installation and supplementary documents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2 instructions for use</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2 emergency routines</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Signs and labels</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><U>Leksell<SUP>&reg;</SUP> Coordinate Frame<SUP>&reg;</SUP>
Kit for PERFEXION<SUP>TM</SUP></U></B><U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92.8%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 23%">Qty</td>
    <TD STYLE="width: 67%">Consists Of:</td>
    <TD STYLE="width: 10%">Article No.</td></tr>
<tr style="vertical-align: top">
    <td>1</td>
    <td>Frame with Feet and Straight Front Piece</td>
    <td>50487-01</td></tr>
<tr style="vertical-align: top">
    <td>1</td>
    <td>Front Piece, Curved</td>
    <td>60638-01</td></tr>
<tr style="vertical-align: top">
    <td>2</td>
    <td>Insulated Fixation Post, Anterior</td>
    <td>912462</td></tr>
<tr style="vertical-align: top">
    <td>2</td>
    <td>Insulated Fixation Post, Short Posterior</td>
    <td>912463</td></tr>
<tr style="vertical-align: top">
    <td>2</td>
    <td>Insulated Fixation Post, Long Posterior</td>
    <td>912862</td></tr>
<tr style="vertical-align: top">
    <td>6</td>
    <td>Locking Screw, 5 x 19 mm, Titanium</td>
    <td>60490-03</td></tr>
<tr style="vertical-align: top">
    <td>6</td>
    <td>Locking Piece for Fixation Post</td>
    <td>60497-01</td></tr>
<tr style="vertical-align: top">
    <td>1</td>
    <td>Ear Plug Holder, Right</td>
    <td>50498-01</td></tr>
<tr style="vertical-align: top">
    <td>1</td>
    <td>Ear Plug Holder, Left</td>
    <td>50498-02</td></tr>
<tr style="vertical-align: top">
    <td>2</td>
    <td>Ear Plug</td>
    <td>60136-01</td></tr>
<tr style="vertical-align: top">
    <td>1</td>
    <td>Fixation Screws, Titanium, kit of 20 pairs</td>
    <td>907999</td></tr>
<tr style="vertical-align: top">
    <td>2</td>
    <td>Instrument Screw Driver, Double</td>
    <td>50146-02</td></tr>
<tr style="vertical-align: top">
    <td>1</td>
    <td>Sterilizing Tray for Frame</td>
    <td>50151-03</td></tr>
<tr style="vertical-align: top">
    <td>4</td>
    <td>Disposable Inserts, 25x4 pieces</td>
    <td>912464</td></tr>
<tr style="vertical-align: top">
    <td>1</td>
    <td>Instruction for Use, Leksell&reg; Coordinate Frame kit 003818</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>1</td>
    <td>Instructions for Use, Insulated Fixation Posts</td>
    <td>012594</td></tr>
<tr style="vertical-align: top">
    <td>1</td>
    <td>Quick Reference Guide</td>
    <td>014611</td></tr>
</table><BR STYLE="clear: both"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>PERFEXION<SUP>TM</SUP> system tool kit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Includes:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92.8%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 91%">QA tool</td>
    <TD STYLE="width: 9%">1001182</td></tr>
</table><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- For radiation focus precision check.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 90%">Frame Cap</td>
    <TD STYLE="width: 10%">717960</td></tr>
</table><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- The frame cap is used during patient preparation
for a treatment with Leksell Gamma Knife<SUP>&reg;</SUP> PERFEXIONTM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>LSS Spare Part Kit for Leksell<SUP>&reg;</SUP>
Coordinate Frame<SUP>TM</SUP></B> Consists of 4 pieces of each of the following;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- Locking Screw, 5 x 19 mm, Titanium</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- Locking Piece for Fixation Post</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">- Screw, 4 x 10 mm, Titanium</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Skull scaling instrument</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">For measurement of skull shape for Leksell GammaPlan<SUP>&reg;
</SUP>modeling</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92.8%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%"><b>CT planning kit</b></td>
    <TD STYLE="width: 50%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>Includes:</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-top: 1.8pt">CT indicator</td>
    <td style="padding-top: 1.8pt; text-align: right">A0800-11</td></tr>
<tr style="vertical-align: top">
    <td>- Fiducial box for CT imaging procedure</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>CT adapter</td>
    <td style="text-align: right">A0400-04</td></tr>
<tr style="vertical-align: top">
    <td>- Fixating the stereotactic frame to the CT table fixation</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-top: 1.8pt">CT table fixation</td>
    <td style="padding-top: 1.8pt; text-align: right">A0401-XX</td></tr>
<tr style="vertical-align: top">
    <td>- Fixating the CT adapter to specified CT table.</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><b>MRI planning kit</b></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-top: 1.8pt">Includes:</td>
    <td style="padding-top: 1.8pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>MR adapter</td>
    <td style="text-align: right">A0420-XX</td></tr>
<tr style="vertical-align: top">
    <td>- Fixating the stereotactic frame to specified MR table.</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-top: 1.8pt">MR indicator</td>
    <td style="padding-top: 1.8pt; text-align: right">A0820-07</td></tr>
<tr style="vertical-align: top">
    <td style="padding-top: 1.8pt">- Fiducial box for MR imaging procedure</td>
    <td style="padding-top: 1.8pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td><b>X-ray planning kit</b></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-top: 1.8pt">Includes:</td>
    <td style="padding-top: 1.8pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-top: 1.8pt">X-ray indicator</td>
    <td style="padding-top: 1.8pt; text-align: right">A0860-04</td></tr>
<tr style="vertical-align: top">
    <td>- Fiducial box for angiography imaging procedure</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>X-ray adapter and support</td>
    <td style="text-align: right">A0440-XX</td></tr>
<tr style="vertical-align: top">
    <td>- Fixating the stereotactic frame to specified angiography table.</td>
    <td>&nbsp;</td></tr>
</table><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Standard LGP for LGK PERFEXION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 9pt Sans-Serif; color: Red"><B></B></FONT>Includes one (1) Leksell GammaPlan&reg; (LGP) license for creating new treatment plans for Leksell Gamma Knife&reg;
PERFEXIONTM .This main license allows the addition, management and storage of an unlimited number patient records and treatment
plans. LGP also allows the visualization of treatment plans created at other LGK units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.1in"><B>Leksell GammaPlan&reg; for
Leksell Gamma Knife&reg; PERFEXION<SUP>TM</SUP> includes:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.1in">1 STANDARD LGP FOR PERFEXION
LICENSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Includes one (1) Leksell GammaPlan&reg; (LGP) license
for creating new treatment plans for Leksell Gamma Knife&reg; PERFEXIONTM .This main license allows the addition, management and
storage of an unlimited number patient records and treatment plans. LGP also allows the visualization of treatment plans created
at other LGK units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1 RETREATMENTTM LICENSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">This software add-on facilitates planning of treatments
days before surgery, the assessment of treatments and re-treatments. Users are free to plan days ahead of treatment, to prepare
tomorrow&rsquo;s follow-ups and plan additional treatment. Re-TreatmentTM also lets any user to integrate images and vital treatment
information from previous plans. It is a powerful tool to import and display previous key treatment data in the new treatment images.
Imported data are user defined regions (targets, risk structures) and prescription isodose. It increases the customer confidence
when treating new lesions after an initial treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1 WARPSPEEDTM, REAL-TIME DOSE UPDATE LICENSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">This add-on speeds up planning by allowing the update
of isodoses instantly during planning. Isodoses displayed in any workspace are instantly updated whenever one or several isocenters
are added, modified, or removed. It is possible to fully apprehend the potential of composite shots, while also simplifying the
elaboration of new dose plans. WarpSpeed&trade; provides a shorter learning curve, more intuitive and faster planning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1 FUNCTIONAL PLANNING&trade; LICENSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">This software add-on allows users to perform some
functional procedures based on the definition on the AC-PC line the visualization of functional targets based on functional target
formulas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1 IMAGEMERGE&trade; LICENSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">This software add-on allows an automatic or manual
co-registration of any frameless image studies with a frame based reference study. Once co-registered, the frameless image can
be used in LGP like any other study. Supports MR, CT and PET images (requires the optional module ColorPETTM).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1 COLOR PET&trade; LICENSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 9pt Sans-Serif; color: Red"><B></B></FONT>The ColorPET&trade; software add-on help users to can combine the physiological data of PET images with the anatomical
data of CT and MR images using predefined color lookup tables. Requires the ImageMerge software add-on.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Color Printer 110V</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">Network color laser printer with</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ethernet connector, minimum speed 10/100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Support for Postscript Level 3 printing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Power supply 110 V</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;English menus and labels</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Support for printing A4, US letter, US executive
and US legal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">Delivered model: HP Color Laser Jet or similar</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Additional Training for Leksell Gamma Knife<SUP>&reg;</SUP>
PERFEXIONTM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Training</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">Principle and practice of Gamma Knife Surgery, clinical
lectures, treatment planning, patient treatment - 5 days. Arranged by Elekta in collaboration with participating hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LGP &ndash; DICOM RT License</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in">DICOM RT provides an exclusive possibility to share
treatment information with any DICOM RT compatible system. It includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify">IMPORT of DICOM RT STRUCT allows
displaying any user-defined region/volume created on a DICOM RT system. Volumes can be target volumes, organ at risks, isodoses
or any other region of interest defined by the user.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in"><FONT STYLE="font: 9pt Sans-Serif; color: Red"><B></B></FONT>EXPORT of treatment data via DICOM RT STRUCT and DICOM RT DOSE allows sharing information with any compatible
systems to perform dose comparison or dose addition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Technical Specifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td colspan="2" style="border-bottom: Black 1pt solid">Workflow</td></tr>
<tr>
    <td style="width: 61%"><font style="font-size: 10pt">Automatic positioning system</font></td>
    <td style="width: 39%"><font style="font-size: 10pt">Couch integrated</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Typical repositioning time</font></td>
    <td><font style="font-size: 10pt">&lt; 3 s</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Typical collimator size setup time</font></td>
    <td><font style="font-size: 10pt">&lt; 3 s</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Blocked collimation setup time</font></td>
    <td><font style="font-size: 10pt">&lt; 3 s</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Mixed collimation setup time (Composite shot)</font></td>
    <td><font style="font-size: 10pt">&lt; 3 s</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Check and verify</font></td>
    <td><font style="font-size: 10pt">100%</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">QA procedure</font></td>
    <td><font style="font-size: 10pt">Automatic</font></td></tr>
<tr>
    <td colspan="2"><font style="font-size: 10pt">Accuracy</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Radiological accuracy</font></td>
    <td><font style="font-size: 10pt">&lt; 0.5 mm</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr>
    <td><font style="font-size: 10pt">Positioning repeatability</font></td>
    <td><font style="font-size: 10pt">&lt; 0.05 mm</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Maximum patient weight</font></td>
    <td><font style="font-size: 10pt">210 kg (460 pounds)</font></td></tr>
<tr>
    <td colspan="2"><font style="font-size: 10pt">Treatment planning</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Treatment planning system</font></td>
    <td><font style="font-size: 10pt">PC/Linux based</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Dynamic shaping</font></td>
    <td><font style="font-size: 10pt">Yes</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Remote planning</font></td>
    <td><font style="font-size: 10pt">Yes</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Image co-registration</font></td>
    <td><font style="font-size: 10pt">Yes</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">PET supported</font></td>
    <td><font style="font-size: 10pt">Yes</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Mechanical treatment range X/Y/Z</font></td>
    <td><font style="font-size: 10pt">160/180/220 mm</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Shape of accessible volume</font></td>
    <td><font style="font-size: 10pt">Cylindrical</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Real collimator sizes</font></td>
    <td><font style="font-size: 10pt">4,8,16 mm diameter</font></td></tr>
<tr>
    <td colspan="2"><font style="font-size: 10pt">Radiation data</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Total cobalt-60 activity at loading (approx.)</font></td>
    <td><font style="font-size: 10pt">&lt; 6,600 Curie (2.44 x 10<sup>14</sup> Bq)</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Number of radiation sources</font></td>
    <td><font style="font-size: 10pt">192</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Radiation dose rate at focal point at loading</font></td>
    <td><font style="font-size: 10pt">&gt; 3 Gy/min</font></td></tr>
<tr>
    <td colspan="2"><font style="font-size: 10pt">Physical data</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Overall length, including cover</font></td>
    <td><font style="font-size: 10pt">4.46 m</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Overall width, including cover</font></td>
    <td><font style="font-size: 10pt">2.12 m</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Overall height, including cover</font></td>
    <td><font style="font-size: 10pt">1.91 m</font></td></tr>
<tr>
    <td><font style="font-size: 10pt">Total weight (approximate)</font></td>
    <td><font style="font-size: 10pt">20,000 kg</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 9pt Sans-Serif; color: Red"><B></B></FONT><B>Radiation
unit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The radiation unit is the radiation delivery system. It houses
192 Cobalt-60 sources and the collimator system that directs the radiation to the focus point. The radiation unit incorporates
the management of the shielding doors and electro-mechanics of the source sectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following section describes selected components within the
radiation unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All components are chosen from well-recognized suppliers to
secure reliability and to optimize performance of the system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><font style="font-size: 10pt">Collimator body with radiation shielding</font></td></tr>
<tr>
    <TD STYLE="width: 26%"><font style="font-size: 10pt">Collimator body</font></td>
    <TD STYLE="width: 74%"><font style="font-size: 10pt">Tungsten body with 576 collimator channels.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Collimators</font></td>
    <TD><font style="font-size: 10pt">Tungsten collimator inserts.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Pre-collimator</font></td>
    <TD><font style="font-size: 10pt">576 lead pre-collimator channels.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Outer shielding</font></td>
    <TD><font style="font-size: 10pt">Cast iron.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Inner shielding</font></td>
    <TD><font style="font-size: 10pt">Tungsten and lead.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Bearing for collimator body</font></td>
    <TD><font style="font-size: 10pt">Crossed roller bearing. Static axial load 680000 N</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Shielding doors</font></td>
    <TD><font style="font-size: 10pt">Steel.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Shielding strips</font></td>
    <TD><font style="font-size: 10pt">Stainless Steel.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Servo Controller</font></td>
    <TD><font style="font-size: 10pt">High precision, fully digital servo drive with embedded intelligence.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Motor</font></td>
    <TD><font style="font-size: 10pt">DC motor with 2000 line encoder</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Linear guide</font></td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <TD><font style="font-size: 10pt">Linear guide blocks</font></td>
    <TD><font style="font-size: 10pt">Caged ball technology.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Gear</font></td>
    <TD><font style="font-size: 10pt">Planetary gear</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Clutch</font></td>
    <TD><font style="font-size: 10pt">Ratchetting clutch</font></td></tr>
<tr>
    <td colspan="2"><font style="font-size: 10pt">8 source carrying sector units</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Sector</font></td>
    <TD><font style="font-size: 10pt">Aluminum. 24 source housing</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Shafts</font></td>
    <TD><font style="font-size: 10pt">Induction hardened stainless steel.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Bearings</font></td>
    <TD><font style="font-size: 10pt">Graphite bushings</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Motor</font></td>
    <TD><font style="font-size: 10pt">24V DC motor</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Encoder</font></td>
    <TD><font style="font-size: 10pt">500 impulses/turn</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Linear guide unit</font></td>
    <TD><font style="font-size: 10pt">Repeatability: &plusmn;0.003mm.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Linear encoder</font></td>
    <TD><font style="font-size: 10pt">Absolute Linear encoder.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Solenoid</font></td>
    <TD><font style="font-size: 10pt">Photo-micro sensor.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Servo controllers</font></td>
    <TD><font style="font-size: 10pt">Intelligent servo card</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Patient Positioning System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Patient Positioning System is the component of the PERFEXION&trade;
system that the patient reclines on for treatment and is positioned relative the point of focus in the radiation unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following section describes selected components within the
Patient Positioning System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All components are chosen from well-recognized suppliers to
secure reliability and to optimize the performance of Leksell Gamma Knife PERFEXION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><font style="font-size: 10pt">Couch framework with X/Y/Z drive</font></td></tr>
<tr>
    <TD STYLE="width: 32%"><font style="font-size: 10pt">Framework</font></td>
    <TD STYLE="width: 68%"><font style="font-size: 10pt">20 mm zinc chromated steel</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Motors</font></td>
    <TD><font style="font-size: 10pt">DC motors with 2000 line encoders.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Gear</font></td>
    <TD><font style="font-size: 10pt">X/Y-axis Planetary gear 30:1 Z-axis Planetary gear 4:1</font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">Ball screws Bearing houses Support bearings</font></td>
    <TD><font style="font-size: 10pt">X/Z -axis.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Screw jack</font></td>
    <TD><font style="font-size: 10pt">Y-axis: Integrated safety nut.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Linear guides</font></td>
    <TD STYLE="vertical-align: top">&nbsp;</td></tr>
<tr>
    <TD><font style="font-size: 10pt">Linear guide blocks</font></td>
    <TD><font style="font-size: 10pt">Caged ball technology.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Solenoid</font></td>
    <TD><font style="font-size: 10pt">Y-axis: Photo-micro sensor.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Linear encoders</font></td>
    <TD><font style="font-size: 10pt">Absolute Linear encoders. Accuracy grade +/- 0.005mm.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Servo Controllers</font></td>
    <TD><font style="font-size: 10pt">High precision, fully digital servo drive, with embedded intelligence.</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Frame fixation</font></td>
    <TD><font style="font-size: 10pt">Hardened stainless steel</font></td></tr>
<tr>
    <td colspan="2"><font style="font-size: 10pt">Comfort system</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Mattress support</font></td>
    <TD><font style="font-size: 10pt">Sandwich structure with aluminum honeycomb core and steel sheets</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Actuator</font></td>
    <TD><font style="font-size: 10pt">DC actuator</font></td></tr>
<tr>
    <TD><font style="font-size: 10pt">Ball bearing</font></td>
    <TD><font style="font-size: 10pt">Stainless steel.</font></td></tr>
<tr>
    <td colspan="2"><font style="font-size: 10pt">Covers</font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">Radiation unit and couch covers</font></td>
    <TD><font style="font-size: 10pt">3 layers glass reinforced polyester. Meets ASTM E84 with flame spread index less than 75. Flammability rating V-0 according to UL 94.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Control System<FONT STYLE="font-size: 10pt"> </FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Office Cabinet</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>MCU - Main Computer Unit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Office UPS - Uninterrupted Power Supply </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Ethernet Switch</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Operators Console</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>CIU - Connection and Isolation Unit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The CIU is powered by the office UPS and the internal power
supply converting 100-250VAC to 24VDC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>PSS - Patient Surveillance system</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The PSS is included in the operator console as a separate unit
and handles the video/audio signals of the PERFEXION&trade; system. It is possible to connect a video recorder on the &lsquo;auxiliary&rsquo;
outputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">External audio system, e.g., patients MP3 player, can be connected
and played over the sound system integrated in the radiation unit covers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>MCU Monitor</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">19&rdquo; Flat screen, UL-approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The MCU Monitor shows the Graphical User Interface of the MCU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>PSS Monitor</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">19&rdquo; Flat screen, UL-approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The PSS monitor shows the video from the patient camera and
provides the sound from the patient microphone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Treatment room Monitor</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">19&rdquo; Flat screen, UL-approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The treatment room monitor displays the same information as
the MCU monitor on the operators console.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Treatment room Camera</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The treatment room camera provides video to the PSS Monitor
in the Operators Area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Medical Cabinet</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>SDU - Sector Drive Unit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SDU contains 8 servo controllers (one for each sector).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>ECU - Electronic Control Unit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Control Unit consists of two complete Power PCs (PPC) with
peripherals (RAM, ROM, inputs, outputs, CAN interfaces).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Medical UPS - Uninterrupted Power Supply</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The medical UPS delivers 24VDC and 48VDC needed for the PERFEXIONTM
system. It is approved for medical use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Radiation phantom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 9pt Sans-Serif; color: Red"><B></B></FONT>The
Radiation Phantom with Cassettes is used for calibrating the absorbed dose rate of Leksell Gamma Knife&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: black 1pt solid"><B>INFORMATION TO BE FURNISHED BY BUYER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not later than six months prior to the Contractual Delivery
Date or two weeks after the Effective Date, whichever occurs later, Buyer shall inform Seller in writing of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the orientation of the LGK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the minimum lengths of cables required to connect the
LGK at the Site; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font: 9pt Sans-Serif; color: Red"><B></B></FONT><FONT STYLE="font-size: 10pt">the manufacturer and model numbers of the CT, MRI and angiographic equipment which
Buyer intends to use in connection with the LGK.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B<BR>
DESCRIPTION OF SITE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TUFTS MEDICAL CENTER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">750 WASHINGTON ST STE 1012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 9pt Sans-Serif; color: Red"><B></B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BOSTON, MA 02111-1526</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT C<BR>
ELEKTA'S WARRANTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subject to the exceptions set forth below, Elekta warrants to Buyer
that for one year from the date of completed Installation Test Protocol, the LGK will perform consistently with the Specification
and the LGK will be free from defects in design, materials, and workmanship which result in non-compliance with the Specification,
except as otherwise provided herein below. Notwithstanding the foregoing, Elekta&rsquo;s warranty set forth in this Section 1 does
not cover:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>defects arising out of materials or parts provided, modified or designed by Buyer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;defects emanating from Buyer&rsquo;s improper
use or maintenance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;normal deterioration or normal wear and tear,
including radioactive decay of the Cobalt Supply;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD>defects resulting from repairs or service of the LGK supplied other than by Elekta or its authorized representative;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD>defects in the Hardware (and its operating software) (the warranty for which is regulated in Section 7 below) or the LGP Software
(the warranty for which is regulated in Section 2 below).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD>the training referred to in Subsection 3.2 of the Terms and Conditions; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD>defects in positioning or in the Site.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Elekta warrants that the LGP Software will, for a period of one year from the date of the completed Installation Test Protocol,
perform substantially in accordance with the documentation delivered with such LGP Software. The warranty set forth in this Section
2 shall not apply if the LGP Software is subject to unauthorized repair or modification, improper application, improper installation,
accidental damage, negligence in use, improper storage, acts of God, electrical power damage, equipment malfunction, or abnormal
operating conditions, and in the event of any of the foregoing, Buyer shall be responsible to pay Elekta&rsquo;s then standard
charges for any repairs, replacements or services performed by Elekta.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD>In the event that the LGK or any part or component thereof shall fail to conform with the relevant warranty described herein,
Elekta shall (or cause one of its Affiliates to) promptly repair or replace, at its option and at its expense, the defect in the
LGK or component thereof. Repair or replacement parts furnished or work performed under this warranty shall be warranted for a
period of one year from and after the date of such repair of replacement, but in no event shall any such warranty with respect
to repair or replacement work or parts extend past that date which is two (2) years from and after the date of completion of the
Installation Test Protocol. The defective LGK or part thereof which is replaced in accordance with this warranty shall be the property
of Elekta, and Elekta will notify Buyer in writing immediately after repair or replacement as to what disposition Elekta desires
of such LGK or part thereof, all at Elekta&rsquo;s cost.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD>In order to avail itself of its rights under this warranty,
Buyer shall immediately notify Elekta in writing of any defects that appear under the warranty and shall give Elekta every opportunity
of inspecting and remedying such defects.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">Year 2000 Compliance Warranty. Elekta further warrants
that the equipment, software and use of data will be year 2000 compliant and accommodate a full year calculation in its software.
Licensor will guarantee that the equipment and software will accept all data and perform to comply with the year 2000 warranties,
assuring that the full four (4) positions (e.g. 1997) year is utilized.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: left"><B>THE FOREGOING WARRANTIES ARE EXCLUSIVE AND GIVEN AND
ACCEPTED IN LIEU OF ALL OTHER WARRANTIES OF ELEKTA OR ITS REPRESENTATIVES WITH RESPECT TO QUALITY, PERFORMANCE AND OPERATION OF
THE LGK, WRITTEN OR ORAL, EXPRESSED OR IMPLIED. ALL OTHER WARRANTIES OF ELEKTA OR ITS REPRESENTATIVES, INCLUDING, WITHOUT LIMITATION,
ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY EXPRESSLY DISCLAIMED. CORRECTION OF NON-CONFORMITIES
OR DEFECTS AS PROVIDED ABOVE SHALL BE BUYER&rsquo;S EXCLUSIVE REMEDY AND SHALL CONSTITUTE FULL AND FINAL FULFILLMENT OF ALL LIABILITIES
OF ELEKTA, WHETHER IN WARRANTY, CONTRACT, NEGLIGENCE, STRICT LIABILITY, TORT OR OTHERWISE WITH RESPECT TO THE LGK. IN NO EVENT
SHALL ELEKTA BE LIABLE FOR LOSS OF USE, REVENUE OR PROFIT, OR FOR ANY OTHER DIRECT, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGE
ARISING IN ANY RESPECT FROM THE LGK OR ITS USE, OPERATION OR PERFORMANCE. THE PROVISIONS OF THIS PARAGRAPH SHALL SURVIVE THE TERMINATION
OF THIS AGREEMENT.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 9pt Sans-Serif; color: Red"><B> </B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.</FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Elekta shall assign to Buyer all of Elekta&rsquo;s rights under the
warranty or warranties provided by the manufacturer (the &ldquo;Computer Manufacturer&rdquo;) for the Hardware and operating software
included in the LGK. In the event the Hardware or operating software exhibit defects which are covered by the warranty of the Computer
Manufacturer, Buyer may notify Elekta of the nature of such defects. In such case, Elekta shall promptly inform the Computer Manufacturer
thereof and use its best efforts to arrange prompt repair service by the Computer Manufacturer pursuant to the terms of the Computer
Manufacturer&rsquo;s warranty or warranties Elekta shall furnish Buyer with such reasonable cooperation as Buyer may request with
respect to the purchase by Buyer of any extended warranty or maintenance contract offered by the Computer Manufacturer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEKSELL GAMMAPLAN<SUP>&reg;</SUP> PFX<SUP>TM</SUP>
SOFTWARE LICENSE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">LGP Software</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1</TD><TD>Elekta hereby licenses to Buyer at no additional cost beyond the Purchase Price, the LGP Software, to be utilized only for
the purpose of planning dosages of treatments to be performed with the LGK. In case Buyer already has an existing Leksell Gamma
Knife<SUP>&reg;</SUP> Buyer may also retain one license to the old Leksell Gamma Plan<SUP>&reg;</SUP> software for archival purposes.
Such license is also subject to the license terms and conditions set out in this Exhibit E. Such license is for the use by Buyer
of the software at one (1) workstation.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2</TD><TD>Buyer shall not: (a) use LGP except in connection with the radiosurgical operations performed with the LGK at the Site; (b)
make any modification to, adapt, translate, decompile, disassemble or create derivative works based on LGP or merge LGP into any
other software; (c) reproduce LGP (or any portion thereof) or any materials related thereto except for one back-up copy made as
part of Buyer&rsquo;s regular computer software maintenance routines; (d) transfer, assign or sublicense LGP to any person except
to an assignee of all of Buyer&rsquo;s rights in this Agreement in a manner permitted by Section 8.1 of the Terms and Conditions;
or (e) use LGP in connection with any access terminal other than the Hardware which has been specifically approved by Elekta in
writing.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.3</TD><TD>All right, title, interest and ownership of, in and to LGP, including but not limited to all trademarks, service marks, registrations,
copyrights, and all other proprietary rights not expressly granted in this License, shall at all times remain the exclusive property
of Elekta. Elekta shall retain all rights to LGP recorded on the original disk(s) and all subsequent copies of LGP, in whatever
form recorded.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.4</TD><TD>The term of Buyer&rsquo;s license to LGP shall continue until the earlier of: (a) any sublicense, assignment or transfer or
attempted sublicense, assignment or transfer by Buyer of LGP without the consent of Elekta; (b) the transport, movement or attempted
transport or movement by the Buyer of LGP, or the Hardware on which LGP is installed, from the Site without prior written consent
of Elekta; (c) any modification or adaptation of LGP for use with any equipment other than the LGK; (d) the use of LGP in connection
with more than one access terminal unless Buyer has obtained the written consent of Elekta to the use of more than one access terminal
at the same time or in connection with any access terminal other than the Hardware which has not been specifically approved by
Elekta in writing; or (E) the mutual written consent of Buyer and Elekta.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">Buyer&rsquo;s Responsibilities Concerning Hardware and
LGP</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1</TD><TD>To facilitate E-Mail/Internet support, Buyer shall provide for E-Mail/Internet connectivity.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2</TD><TD>Buyer shall assign a system manager who will undergo the appropriate training on the operating system HP-UX and /or already
have sufficient UNIX system administrator experience. Such training will be provided by the Hardware manufacturer and Elekta shall
pay the fee therefore. Buyer shall pay all travel and other expenses associated with such training.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.3</TD><TD>If Buyer elects to transfer images by a data network, then :</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Buyer shall provide the format to and right to read the diagnostic images generated by the user&rsquo;s
diagnostic equipment and planned to be used as input for LGP. The Buyer shall provide a sample image in digital and hard copy form
in the orientation intended for clinical use.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Buyer is responsible for obtaining up-to-date and accurate scanner image formats and any other
scanner or PACS information from vendors necessary to integrate images into LGP and providing this to Elekta.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Hardware used to run LGP must be used solely for this purpose. All changes and additions to
LGP and/or Hardware running LGP must receive prior written approval of Elekta.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Buyer shall provide the images via an Ethernet connection using TCP/IP protocol and will provide
all physical cabling to the LGP Hardware compatible with 100-Base-T or 1000-Base-T at the Installation location of the LGK.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Buyer shall provide all TCP/IP networking parameters such as IP address, netmask, gateway address,
etc. for the HP workstation included as a part of the Hardware.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT E</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>END USER AGREEMENT AMENDMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
page left intentionally blank.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>PER PROCEDURE PAYMENTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U STYLE="text-decoration: none">Annual Procedures Performed</U></P></TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 31%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Initial Non-Medicare</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U STYLE="text-decoration: none">Fee Per Procedure</U></P></TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Initial Medicare</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U STYLE="text-decoration: none">Fee Per Procedure</U><SUP>1</SUP></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">* </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">*</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding anything to the contrary
set forth herein, (a) for purposes of determining the per procedure payment, the number of annual procedures performed shall be
reset to zero (0) on each anniversary of the first day of the first full month after the Effective Date of this Agreement; (b)
for purposes of determining the applicable per procedure payment tier, non-Medicare and Medicare procedures will be grouped chronologically
as they are performed; and (c) there shall be no retroactive adjustment of the per procedure payment irrespective of whether the
number of procedures performed during any fiscal year reaches a lower per procedure payment level. For example, if during an annual
measuring period, * procedures are performed (of which * are non-Medicare procedures and * are Medicare procedures), then, (i)
for each of the first * procedures performed (irrespective of the number of non-Medicare and Medicare procedures comprising the
first * procedures), Medical Center would pay * for each non-Medicare procedure and * for each Medicare procedure; and (ii) for
each of the next * procedures performed (irrespective of the number of non-Medicare and Medicare procedures comprising the next
* procedures), Medical Center would pay * for each non-Medicare procedure and * for each Medicare procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>DESIGNATED PAYORS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.A
<SEQUENCE>3
<FILENAME>v382020_ex31a.htm
<DESCRIPTION>EXHIBIT 31A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31a</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Ernest A. Bates, M.D., as chief executive officer of American
Shared Hospital Services, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. I have reviewed this Amendment No. 1 on Form 10-K/A to the
annual report on Form 10-K for the period ended December 31, 2013 of American Shared Hospital Services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. The registrant's other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c) Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">d) Disclosed in this report any changes in the registrant&rsquo;s
internal control over financial reporting that occurred during registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. The registrant's other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee
of registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant's internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">June 23, 2014</FONT></TD>
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Ernest A. Bates, M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Ernest A. Bates, M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.B
<SEQUENCE>4
<FILENAME>v382020_ex31b.htm
<DESCRIPTION>EXHIBIT 31B
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31b</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Craig K. Tagawa, as chief financial officer of American Shared
Hospital Services, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. I have reviewed this Amendment No. 1 on Form 10-K/A to the
annual report on Form 10-K for the period ended December 31, 2013 of American Shared Hospital Services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. The registrant's other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c) Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">d) Disclosed in this report any changes in the registrant&rsquo;s
internal control over financial reporting that occurred during registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. The registrant's other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee
of registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant's internal control over financial reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">June 23, 2014</FONT></TD>
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Craig K. Tagawa</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Craig K. Tagawa</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tpg17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg17.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!'`'``P$1``(1`0,1`?_$`.4``0``!04!````````
M```````!!@<("0(#!`4+"@$!``,!`0`#`0````````````(&"00%`0,(!Q``
M``4#`@(#!0\0!P4$"04``0(#!`4`!@<1""$2,1,)05$4%1IA<2)2%M8GE]>8
MN%EIJ0KP@9&AL<$R([4V=A<X>#EYT3,D5-66&.'Q0D,F4T0E&;)C@S0U1<6W
M*&651F:&$0$```("!!D,`@("`P$``````@0!!0.4!QB1L=$2(C)BHK+B,U-C
M<Z/3Y!4E9:465F8($7%R$[,T-76U-G8W%`8A,4%1@5(C%__:``P#`0`"$0,1
M`#\`PJYRP`ENLS[V%6VA:Z5+(1SSL2VEXG5O!*(+/J6P2^=R^X>WS3B<(>1B
M"RQXT'W6@W%TW!42\O6$UU#7C^M_V.G^H_UG^]?V>&Q>OBD*]G[/ZO'8S'^J
MD)./&X[&Q8W'8WR>7&T^3R^7R4_Z4*S6'^19I6P^7R8ZQ0T>7_KRQ14,_'D4
M=O\`QB4S[V-C[NE?GZ_CFNSD-O<$>KU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G
M(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9]
M[&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.
MZ8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV
M<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IG
MWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SN
MF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G
M(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9]
M[&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.
MZ8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV
M<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IG
MWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SN
MF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G
M(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9]
M[&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.
MZ8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV
M<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IG
MWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SN
MF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G
M(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9]
M[&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.
MZ8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV
M<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IG
MWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SN
MF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G
M(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9]
M[&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.
MZ8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV
M<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SNF/(H[?\`C$IG
MWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G(+>X(=6H=>SN
MF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z8\BCM_XQ*9][&Q]W2E_'-=G
M(+>X(=6H=>SNF/(H[?\`C$IGWL;'W=*7\<UV<@M[@AU:AU[.Z9U,_P#0MH"$
M@IJ:#M#)AP,1$24H#<=L[)(%Q8,UG8(BJ&<%!3!44N43`4VFNN@]%?=+>-Z:
ML\Q8[!U=AHQ\<,/E_F_Z\M-%'E]T?%/];AHHII]=_JC_`-=,PM=@G^T9LU_F
M98@^#[G:O[/XA_\`/]?K?\<F?;R[SJIU6Q[=1A4JFXU_B1?1IOW<MAOPN<\5
MYT]^KKI?S&M/IDJG#[[)^A!HXGJ,5E8NY0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"4[]_,6]/T
M3N/\CO*[*N^(6#;H-%0C'E*?-2\L;L$_VC-FO\S+$'P?<[5JQXAOM^MOQR9]
MO+J/5.JV/;H<*E4W&O\`$B^C3?NY;#?A<YXKSI[]772_F-:?3)5.'WV3]"#1
MQ/48K*Q=R@4"@4"@4"@4"@4"@H3EK<_MWP-=N)K"S/FC'.,+TSQ<IK-PS:]Z
MW1&0,WDZZR/H.,-;UEL'RZ2\]+%D;FCT.I0`Q^M>HETU.74*[4"@M\R;NMVY
M89RKA[!V4\PV58N7-P#]]%X7L"X),6EQ9(D(U=BU?-+9:=4<'JS9Q)-R&`3%
M]$J4`Z:"X.@4"@HWGS<)A3:WB^=S3N%R5:^),4VPXAFD_?=XO1CH"*<W#+LH
M"$0=NBIJB123F9%!LD'*/,JJ4.[02#);UMJ$/D+`N*)//./661]T-LM[SV^6
M>M+B$UEJU74:,PVG;.;@B(2$>XC"BL0XF)S$#4*"Z*@QO;@.U_[,G:UDMSAS
M/6]3!^/LGQ[A-I-66[N->;F;9>*Z"1G=Z5L,9M*SG?(('%*4.T4*0P&$`*8!
M$+[L=Y&Q_EVR+:R7BN];5R-CR\XM&:M.][(GHRY[5N2)7,<B4A"SL.Y>1LBU
M%1,Q!,DH8"G(8HZ&*(`$YT"@4"@4"@4"@MXVW[L]MN[ZU;COC;'F:Q\V6E:-
MW/;#N:X+#E?&T="WC'1\;*OK=?+=4EU4DVC9AJN8F@_BUR&`=!H)6PAOIV@[
ME<G9)PW@'<'C?+^2L/J/TLG6O8,R-Q+V4K&SBEMNTIR08(*Q#=0LX@HV(4'!
MA6.DIU?,"9Q*%V%!;Y>6ZW;ECW/&,ML%[9ALJVMP.9HB2GL68FE)(4+QOF'A
MT)IS)R,#'`D8'39FA;KXQS"8O!JIIKRT%([[[2;8EC/<S:VS:^=T&+8#<_><
MK;4#;V&EI9T\NUQ/7D+0+3@7Y(YB\CH*<N0K]N=DS?N&SERDX2.0AB*D,8+W
MZ"E&:\[88VWX\FLM9]RE8F'<:6\"03%[Y$N:*M6W6BSCF!HR"0EG+9)S)OSD
M$C9JEUCERIZ!(AS"`4%N&U7M,=@^]Z9F;9VJ;JL1YFNN`;*/I6S[=GSL;S0C
M45`26F$;0N)K#7*^A$%3%*=\@U5:$,8H"H`F+J%\U`H%`H%`H%`H%`H%`H%!
M*=^_F+>GZ)W'^1WE=E7?$+!MT&BH1CRE/FI>6-V"?[1FS7^9EB#X/N=JU8\0
MWV_6WXY,^WEU'JG5;'MT.%2J;C7^)%]&F_=RV&_"YSQ7G3WZNNE_,:T^F2J<
M/OLGZ$&CB>HQ65B[E`H%`H%`H%`H%`H%!\CGTC/^(U]'1_?M>_\`W4VJT'UP
M*JIHIJ++*$111(=5554Y4TTDTRB<ZBASB!2$(4!$1$0``"@^..[_`*2-OCN]
M7<#NSVF]FRPS;V5FUO)\AC[).?I&_E(/)MWP]MNX]*Z+]LF*&0329PK2-DD)
M`4DX.;3CF#INK(N6O,N5N$A]KCNGP;??:=_1NMY32^8J`V]7/$9%SZ6_;J<(
M0K"#QL_:XNO-:4N(555"1KJ*ASF*Z;\QU$W*9D0`R@``A?QM@[>++N:MJV_'
MM*\@;6(W'?9Z;;&EZ);<Y<TY/DSCN8F(.X$(2",2.D&?J4M:WW+ITT8R3XA7
M:#.6?F;HG<^+7HT%*=J_;0]KQD"[MH63<Y]E/#2VRC>G<-OQMC92VHWC+YKO
MS%5N7@DW=PUZY4BK8F+R2C8>(BW8/9).3C[;5(T;N@#D>-Q9&"X3M!NV(W=6
M/OE_\N'LN=G-N[P]S%A8M;9FS^^OJ[2VK8N,[5DD8M[#V]UY[ALYH-P/XJ=C
M5SN7<LW1(I+L6R"#M=54J`8PNU+[2N'[3?Z-GO"R9(8UE<'YLQ!GO#."]QN$
M)MXJ_?8VRY9FX/%"DNP:/'3*-?.H20;/DU$!<-D5VS@KAFKSJ-3J'#C9J_BZ
M?17/W,(#_P"S#B@^G;M6MR]T[/.SCWC[D;%6*UOS&.#[K?6'(*)$<)Q-]3R:
M%I69-';J%,DY)"7-/M78I'`2*`CRFX"-!\SG98=CWV2T)V36.MZ?:=Q6-[QO
MC=K`*Y/REN%W&91E;5:VH;*UPR:5E0UL7@^NJ";6U<+UF[;.%Y/KAEY";=K&
M,X,GU"*09#^QBQ[MF[-;9GO/@]L^_*,[3?&F+)^\-PD1B?;XA;N0KYQ@P>V_
M/.8;&=MPMA7G?DC/W7D]M9Z)$"`A&MGLT@Y60:DZY<U!9A`?2(.TUQ7>6U3+
M.][LO[;P#L@W@9IC,08^NY*^)AOF>U%YV96BF<A=%O3TD:0\,CV:*TB5I)6U
M;@R[%FL=JH0!(80NQW>=MUO3QIVG><NS!VA;$[<W0Y<M[$=B7QAY\;(8V>T\
M93]J69>MVW!EQ]//86WX6Q+6AIMX@B"#YLX?2)F+<%TS.!H+!K,^DU=H_F_;
M?F.]<"=ES`W#EG9(6[IS?U/W'?JS'#>,+4MI[)$;(6)"J7+%7Y-W@Z86W.+R
M4>#I^K#HPIUB$?IK_B`O6W._2.I3#VR7LN=[>,]L@9&M[?G>LM:E]8K"Y)!:
M^K0D+/DVMN7C;&-7;%@@RNFXUKK:2#")5>H-TG7*V4.B3K#$(%OL7](6[4:S
MMU-T;",W]DQ$Q^]?*=EP=Y;1,.6+F2&>13II/IO98SC--]/)^1ML;7MNT(67
M?R$M&KQW5.H19DNU:`J9VU"^GLV.V_RON>PAVAZ^Z#:9.6!NR[-F3F([+6`L
M%)3=_P`ID)\W9WJE$VQCV"*I<,N:\7-W8^DH=1NF[DV9C&;.TG)D5CE1"QFQ
MOI"?:9XURCLWNW?CV9%K;?=GF^/+L+BG%EX1M\2Q,MVHO=$VSA8N5NVWIV6<
M/NLC4I)*049R4!;2\E&I++-=!*4@A]C-!Y,6VKMD9'8=V5FZ'9O@.Y7%L;IM
MUF]G+:LKD(A)%HA@S`DI8.+[3F;XCI9BBLZ+?-VR$<_C8P6B:KF+;-W;\HIN
MB,04#[G]K>VC#782]C'EW)6W%I:&<;TL+;E=VZF_<I+*J-(S<AD&(QVYN^.E
M3S,=U\@TQN=DFFT@&R)S@TBC`IJHZ<.G"X8D;E^D[]H+`[9L`]H`?LO(=ML,
MN.>@;!RYEF3R0="=N/("TQ*15U$PU$DE1E86RXN1BG$5'3$W%/F,C,-%$#K-
MC&*0`R$[NMS>$5^W-[)6UFVU3'.5,C9MVVY&R#AK<W<%WW]"Y"Q?#.+"S;<<
M?;MNVG$3#:Q)1E<K9F=%564;.%40E5A(8HIIF`,`'9(WON(OWMU]]F>=U79]
M885G;9R(PR)NUR!?UPVK=3[LY"VA;5_7%'71C28?S<HK*/)>1M)JR5=Q`/G#
M9LQ()#II`;4,EJ/TEO?)(6E,[^X?LQEI#L>H++A<;OL\%O;J\X>IL+N0L=3)
M*=NJ2Y6!V*<^Y3;G;%AS124LH$4>:!<#KE#B=IYG\V:+OWI[]$AQ#E#$/9KS
M^Q3!>RZT,[6^>_\`;,AE?=V]P??V<=VF1\=J2D&UNJX;-Q1FV%C+<5>N00AT
MVJ[TB:;D`/0=&[>WUOF:[WI2&O791EO=)V8F)\=;M]E?::=GK8[^P[9:9(:P
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M4O,',`T&0?"_TCWLP=]V2;?V>80O?,Z>6=PZ%P8TL16?Q#-0$.A.S=LS/4N'
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M;.-O>ZO"MGY(P9N%VDW==ME/;FF;<M#&-MRUA7;)6C9]Z2\U`LY:RI5J+1NU
M.=G()1BJY4T'*:P!(N1K$VS>35=I5N&VN6-O4M2Q]PVZ7;Z]D+GWIW_8V0+F
MRW.65GNPT'^3;(E[/M>U73V)FGMQKH2;R02<+.)AHND5=46RAA#(;FE1,W:Y
M_16Q*H0P#LNMTP"!BB`E5PRX!,P"`\2J"'H1[O<H/JN[1;:XOO5V,;J-J[!\
MTC)S-6&;PM&U)*0$Q8Z/O<6(REBO9,Q"F4+&-;PCF)W(E`3`@4_*`CI0?$UM
M9[7#L]\;=FS_`.3]VY^W?.4'?NTV74L>5Q<WM&\O9$C;"N]]<^.4FTK9MVVC
M+V_<=MBJDQ+X0];0DDT:MWB3U5%R=-(.E[&6Z,W[<]C7T@;?WL@VTY$PSC*[
M8ZWKKV-1MXP;^YRQ=IVE,YG=.QM]S.GEQR.YP78=Y-'KQR(R,>N\:BDHJX$J
MY`#$5N+R]MMS)@WLZ=P4QOJW:[RM\UP[A,9WKN[/F^Y;VDL.;6;<"5507L.&
MCYV`;VO;"TG<+(IXUPTE'9'T=%N5R(M$3IH@'UV8#4;J_3"-[!BG04.'9T66
M*8E,F<X`:)VK&,)!`1$`,FJ01TZ2F#N"%!8QV58MR;$?I53C5$IOUG[WA57U
M(!O!T\59P.D*BG_8IB=02ZCRAJ80[M!8!('05[*?Z*B0QDE"'[0N\RG(82'*
M8J>[=5)<IBCJ!BD,/*<!X`/`:#/+F$J)OIB.U,5`3,=/LW+B,@)P*)B+"UW)
M%$4M>)5!;G.`Z<>01[FM!CCPUGG.FVG,WTP#.VV-NH\SCC7)%I35E.&D4A<#
MJVP5RWG6'N:^$8=PW>M'JV/;5>2,T4CA%9L!XW59,Z93D$,)N9\K;8<I0?92
MYZ_UR[L=YN\VX-QF$;WWFSN>;EO:3Q/MB(]N2$7/C&";W)!M;=MQ9>X8F0.Q
M5:R;X'T9"+N@(V0432`/6GH//&^C\=E#ME[0;LUNU14O6TX5SG3,F9K_`-O=
MD97F$TI1?%[>RK=L#+6-Y.UDQ055A.7*<TV?S2C8Q5I5@R0:G,"11*<)][/'
M?A=U\]A%VNG9@;D5W,+NE[//:INEL=C;EP.2C<,AA>*MF[;9\4]6H(JNU\*W
MNDM;S@2:I-HMS#)EUU$:#;W4`@3Z%=MN!($BE%3$8@!`(`"N;=+<IW`AR\.M
M,J)Q/W>;77CK0759F43-V^7T;8"G(/\`^`RQ]"F*/H%,(9K!,W`?P3B4>4>@
M=.%!U^QK%]P9S[27Z6'A6SETTKLR[8TQC"UU3."-TB7%?-M9SM2(ZYP8P$01
M+*2B95#"(`0NNHA0?.#MWF^S9LW8<SV];NLR=KH]W@Q&:)G"&0.S8P5E1_9U
MA3SI_D]Z\925M6'=F*KGL)JHT4.B#V&>.%)=Y=B)@3;%*NFX*'T9;UMKD-LQ
MLB\=M>2Y>;P/L/W_`%L]FQ=-L;@,^,E+^MS;+N9V5'PI;5X86W4RF/XU]#QG
MZ^<,X@AT&EPE32@#W,R=(FZMD*JZ(5,R)ES%6+L@[W]F_9$Y]P%N95[56`B&
M^%=K>VU\WO*T]EV5[_MA/&NYC=#=UWX\"6Q?B_!JF/W*-RNV*S@D@K<[=LBS
M8>#K+J%#ZR\!8@@=OF"L+8%M9==U;.$L3X[Q);SIT4"NG4)CFT(>SXMTY*!C
M@#EPRAR'4XCZ,P\1H*MT"@4"@4"@4"@4"@4"@E._?S%O3]$[C_([RNRKOB%@
MVZ#14(QY2GS4O+&[!/\`:,V:_P`S+$'P?<[5JQXAOM^MOQR9]O+J/5.JV/;H
M<*E4W&O\2+Z--^[EL-^%SGBO.GOU==+^8UI],E4X??9/T(-'$]1BLK%W*!0*
M!0*!0*!0*!0*"0;YQ3B[)Y8TF2L;6#D,D,9T:'+?-G6]=I8HSX&X/C1I9^.D
M`8F>`T2!44N7K.J)S:\H:!*]O;<MO5HS4?<EJ8'PS;%Q1*_A,5/6]B^R(6:C
M'/(=+PB/E(V#;/F2_5*&+SIJ%-RF$-=!&@YL_@3!=UW]#Y6NG"V)KERC;O@W
MJ?R3/XYL^9OZ"\#$!:>)[QD8=S<,9X*)0ZOJ').33T.E!-DW8%B7+/6[=-QV
M5:4_<]H*JKVG<<W;D/*SUKKKF2.NM;LN^9KR$(JL=`@G,V42$PD*(]`4&D,?
M6$%Y#D4+(M`,@FCO$YK["VH8+R-$<I2>*QN?P+QV,=RD`.HZ_JM`#T/"@DJT
MMNNWVP;TE,DV+@K#=E9$G/"AFK^M+&-DVY>DQX<)C/?&ETP\(SG)#PPQA%7K
M5S]8(CS:T'>Y+PYB+-$2T@,Q8KQQEB"CW@2+"%R78]L7W$LI`I0*5\TC;IBY
M5FV>`4-`5(0I].[0=G)XVQU-6<ACN8L&RY;'[9M',FUBR=K0;^SF[.(405B6
MB%L.F*L(DVBU6R9FZ94`(@9,HD`HE#0-"^,L;N9>U;@<X^LAQ/6*R+&V1-KV
MG`JR]G1Q$?!BL+5DE&!GMO,BMQZL$FAT2`3T.FG"@G>@HWD3;IM]R_,1=PY9
MP5AO*,_!E3)"SF1,8V3>TQ#D24,JD6+D[E@Y-['E35.)B@D<@`81$.-!5EK'
ML&+%O%LF31G&-&J3%K'-6R+=BV8H)%019MVB1"-T6J*!0(5,I0(4@``!I049
MBML6VN"@)NU(3;U@Z&M:YIM&YKDMJ*Q-84?`7!<C<%P;W!-P[2`1CI:;0!TK
MR.UTU%R]8;0X<PZA4%ICVP8^[75_,+'L]E?3Z+1@WUZ-+:A6UVO(5N1HFA#N
MKC19$F'$6B1@@4C<ZPI%!!,`*'(70.)%8MQE!,+JBH/'-B0T7?:KY>]XV*M"
MWXYA>2\HDNWDUKJ9M(]%O<*LB@Y4(N9V585B*&`^H&'4.O'"^'1BK4@AQ/C0
M8.PY$\O8\,-B6L,59DLH[\8*2EJ1WBKP2W9$[_\`'BNS(BJ*WHQ-S<:#OEK!
ML1Q>+7(;BRK27R`QC30K&^5K<AU;Q9PY_">>):W,=F::;QIO#%M4"+@D/6G]
M#Z(VH;</CO']NRET3=OV-9T'-7PL#B]9>'MF%C)2[W`&=&!>Z)!DR0=W`L!G
MRP\SLZQM5C\?1FU"G\3MBVUP%NR-GP6WK!T+:4O/IW7+6M$XFL*.MV4NE%-P
MBC<LC",X!&,>SZ23M4I7BB1G!2JG`#Z&'4*X``%`"E`"E*``4H`````&@``!
MP``"@E*SL?V'CM@\B\?V3:-BQDC(*RTA'6=;<-;#!]*KI(H+R;QI",F+=S(+
M(-TR'6.4RAB)E`1T*&@2Z?".%U9FYKC5Q#B]2X;TCI2(O&>/8%J'F;LB9P$@
MFHNYI0T2+Z=CI@$">%(.CJIN.0O6%-H%!V+O$^+']E-L;/L:6`]QTSZGP.P7
M=FVZXLIIX,Z,^;^#6LM''@D.H>G%8G*@'*J(G#0PZT'*6QMCIS/VW=;BP;*<
M739K`8JS[D6M6"5G[4BQ07:C&VW,'8&D8)@+9RHGU+51)/JU#%TT,("'(A+`
ML2VIZXKIMRRK2@+GN]5)>[+CA+<AXJ>NA=`RIT%KBEV+-"0FU43KG$AG*BHE
M$YA#I&@E)Q@/!3O)"&9'6%L2N<O-2D*VRJXQS9ZV2&Y4T0;IE0OE2&-<Z14V
MY0(`%=!H0.4.'"@GZY;9MN\X&5M6\+?@[KMB=9JQTY;ERQ+"=@9F/7``68RL
M/*-W4?(LU@#T22R9R&[H4%,L/[;MN^WEM*LL!8&PSA!I/+%<3C7$6+[)QLWF
M5R&,8BTJC9T'#)R"B8G'E%8#B770-`H*TT"@4"@4"@4"@4"@4"@4$IW[^8MZ
M?HG<?Y'>5V5=\0L&W0:*A&/*4^:EY8W8)_M&;-?YF6(/@^YVK5CQ#?;];?CD
MS[>74>J=5L>W0X5*IN-?XD7T:;]W+8;\+G/%>=/?JZZ7\QK3Z9*IP^^R?H0:
M.)ZC%96+N4"@4"@4"@4"@4"@4"@4"@4"@4'PP[R-\\9`]J[VD6'=SW:[[\]C
MV.L2W1MS9[=\=;9,?W/DFV)")NW`%L7)D8\DE;.)\C!;JC*YEFZZ)'"C4SD\
M@N8O6`0>K#+OF;MJ&6S-%]@BT-N&Z#?.]VV[%\&;M<HY^1G\;V<\F]O\O".F
M-TYGR.6\%K6>M+Y(VA4I1W$,XPSR0<OG'5MVR+1PHF'1=H3VUCJ,Q1N)QSLX
MP#N'RY/P/9V.=TV0]Q&,']BVVVVA6_GW$=RSFWN^9R'NR::2USW"P$$+@D6,
M4"SJ-B&ZCM(COP=PFB$R;N]R^X&Q_HU+7=-:N7+QA-QP;!=K615,RQLBFE>R
MU]W7$8>6NBZADP;]7XUGUIIX9PH5,O-X2<0`NH:!,&ZG=ME+#7:+]C?!/<IW
MK#X-R'M=W]95W%6=$',[C<C_`*F=L]G7]!2\_#H-SN)F3MF05=/61$A(<7)]
M`UYM!#O=JO;I6GG[%^6=PV2MI&:\![8L?[=[LW0V[N!/>&)\TV+<^.+0T5>6
ME=:N([IG3XCSS*L3@M'V1.'3EG)4EBB)#)E!0*?,?I!]FP6&]R61,V;.<V80
MOW!.VW'6\BT\.W!?6*;IG<S[8LG9"B,;060;=N.S9Z7@K4N"&N":;$FK>E^H
MD8P[A),W.<QP3#+QL[W&7GN=P1%9OR'MYR)M84N&2G'$%CK+\G;CF\SV&W43
M7M>]YM.WG3J/@"W3#*E=^`*JG69<2*'-H!Q#YP.RE[2'=GF/M-INZ<[9'F9W
M9'VG#?=W)]G3:LHZ,:)M-/9?EL+3%A`ME&+9%DI>6,6\A*/.J4/X4NW34XZZ
MT%\$)V^MM7+E7%D1`[*MP[[;9G[?%`;#L"[OSSV-FV+LD905ON3L"\)T+<4G
MAOF`M>"E(5ZO%K+,U`GF[!T1,S=TV5;@'3VK](+MBXL6YPS8\V2;AH/%F,\G
MFVX8RNEW<..S%W'[KWN:#8@M[`^*FJLJT$5GY54I=Y./3H,(YJD\2.519J4%
MPGL>W8LMKA.7E)7:MEN.WDQ.ZNV]E@;'0OK$[R[W^>;QLT<EVR#7,S6Y38D+
MBJ1QLDM+'NM1T1@@1NHF<G]6=0):4[?:W)J#VV0F,=E6?\H[B]P>7]V.VM_M
MH@;NQ-&WEBO<AM%@;<G[]QU=UW35T,["?6\^C;F0?I7$R?*,488!>'3$P^#T
M&G:M](&QQN4R'M?A9W:3GS!.(-U4'G*.L'/^2IC'JUF$S#MEM&;O7/6.E8*W
MIR1NGU.6-%VX]02N9PW9MY%^W411:`"2ZB(:\2?2`\:9';W7/7-M6S3BFR+E
MVO[CMW.T&[+ONO&#T-V>*=LEN.KJOIM'0-NW%*3F'[S?V\FC(L(VXDB]=&*^
M$BJ4H)E5"D$M](#O6_\`#&<GV.MC.=<49/D.S<NOM`-H,EDVX,32L/E[&\.V
MB(>>O=Q$Q5U*HP47C:3N'Q]XND'*;^X;=BE5444%7;)!P&5[LHL_YGW0]GIM
M1SEN`LNXK.RI?V&;"F[F=W*_LUXZR*N]M:(=DR_'-K%,$'!6_E3P@9J/C!2;
MN8YH[(W61343$M!D-H%`H%`H%`H%`H%`H%`H%`H%`H%!*=^_F+>GZ)W'^1WE
M=E7?$+!MT&BH1CRE/FI>6-V"?[1FS7^9EB#X/N=JU8\0WV_6WXY,^WEU'JG5
M;'MT.%2J;C7^)%]&F_=RV&_"YSQ7G3WZNNE_,:T^F2J</OLGZ$&CB>HQ65B[
ME`H%`H%`H%`H%`H%`H%`H%`H%!\YUV[%NV)PCOZWZ[J-AN5.SL98YWMW)@:X
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MP-M=3VR6#>DC*3%SYILV'Q]-YFRZWRBQC8-W*M[;AT3GB&:(QSMV0`!)JB*I
M7`6?8(^CKYZ=7KN;>Y_N;9QA&W,V[-<T[4I]YL8LW)EE(;@KMR<]CWMK;@<T
MX=N!2!P_8$QCQY&(OT;?M!FC'N9(5!!1%#E*(:[3[`+="]VD;R,)W!;?9?8-
MR/F/;!8>V+%UP;7L*W9:`W6M;F2+)O>],Q9URI*6D?(C>4R"A8K,%[;B6CV%
M3>IIN``BB8F.'T?[IL2YKR'LHS+@G`5TV=9^;[XP-/XFL6];N=3C&TK6G[DM
M4UH+W2X=0,--3B(PC-ZN[9]2R5.+I)(#%`HF$`P+VY]&JQYMIB]@>6=EUYN;
M7W>;1<P80OW(5WY6R[F*<Q/E"TX>(6C=QMJ6]9@A=$;8)LL+/%E&PQL6S(DD
M84%!(0XB4,-.-Y^=_P!3>QKL[<&;CK1R7B#;CVY4'FFS=H#_`&\Y:L'>?BJU
M(3)V2,J98N?<'.SXJ8];XJPD%R2!8N1BCN37(::!THHV(T!F@&=VZ>PXR?>_
M97S>R:Y;]P?*9CMW>_?6]3&$C<D)=5X8$N"7D,Z75DRW<=YA@'$7!7++VA<E
MEW8[A)Y)JBIU0N!.CX21,"JA0:X^P!S%?.UB%:SF.>S!LW<59&\6#W06EMYQ
MI@6X;=V/W'8,+8DGCU?`68)!O$-LH9&"8C9UT_"Y'<>=Y'O`(W;I=2(K%"YC
M;'V.6<,/Y;[-;,<XMLPQTXVLYKWQ9GSGC3:_BR4Q'CK_`/*#"]O8FQY9V)8]
ME;Z:][KX_96TU1D9^YS,)5\R33*85SI%$P2C@KL/,UV-C#LR,79'R7B.:A=G
MF5NT<N?.!K8?WL1:\;(WMP68K=M^/QLM(V>T$;@MZ/R:F,AXR*R0242.*"CC
ME+SA0+:I]'ZW"80M/*V,;BB.S3A8F$V<;G=LN&,ZXHP'<,9N7S/>.;\=71C.
MS\I[AL@ST,Z?8Y5MJU+D4:S+:U5Y,TR*RXJBJ!BT%VS+L:LW.D-N43-Y5Q8U
MC,6=A[D[LM+T?107:^?N,JY"M.U[9)D:UV#RWV#=_CZ.&&66$';AG(G`2%\'
M]$82!D[[,S">XW;7LAV_[=]T3S#$EDK!-@V]B"/E,%.KT>V9*V!CB&CK1L.5
M?.+[CHF94O"2MZ(26ENK;(LP=G-U!"DT*`7Y4"@4"@4"@4"@4"@4"@4"@4"@
M4"@E._?S%O3]$[C_`".\KLJ[XA8-N@T5",>4I\U+RQNP3_:,V:_S,L0?!]SM
M6K'B&^WZV_')GV\NH]4ZK8]NAPJ53<:_Q(OHTW[N6PWX7.>*\Z>_5UTOYC6G
MTR53A]]D_0@T<3U&*RL7<H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!
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M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"4[]_,6]/T3N/\`
M([RNRKOB%@VZ#14(QY2GS4O+&[!/]HS9K_,RQ!\'W.U:L>(;[?K;\<F?;RZC
MU3JMCVZ'"I5-QK_$B^C3?NY;#?A<YXKSI[]772_F-:?3)5.'WV3]"#1Q/48K
M*Q=R@4"@4"@4"@4"@X3]L1VW%%0[I,HF*83,WCIBOJ4=0`'#-5%<I1[H`;00
MZ:#H_$#/37PRX-/THN'7S]/&5!J]3[$`U%[</?T]5%P:Z>=XRH(^IYCIKX9<
M.G<_ZHN$.X'_`.H]^@@%O,]>+VX/."Y[A[@AQU\94&KU/,N&KRX?\T7#T_\`
M[C0/4ZR_OEP_YHN#_$J!ZG67]\N'_-%P?XC01]3K+^^7#P__`+1<'^)4&H+:
M9#TO;A#_`/U%P_XE0/4VQ#I?7!_FBX/\2H-(V\P#_OMQ?7N>X`_^IT&@8"/#
M_OMP_P":+A_Q'2@T^(H_^^W#_FBX/\2H'B*/_OMP_P":+@_Q*@>(H_\`OMP_
MYHN#_$J#4$`P'_OMP_YHN'_$:#6%O,!_[]<7^9[@_P`3H-7J;8CT/KA$?TGN
M$/\`ZE00]3;/^]W#_FBX/\2H(#;K(.`O+A_S1<'^)4$/4\Q_OMPZ=S_JBX?\
M2H-(V\R#B+VX=.&G_4]P?XEW:`-OL@T_MMP\1X:7/</'S/\`XE0:1@&8"/\`
M;+@X=^Z+AU\[A):<*"/B!E_>[BU[O_4]P]/<_P#F5!I\0,_[Y<.O>]4]P_XE
MKK0/$#/^^W!YWJGN'3S_`/XETT#Q"S_OEP?YGN'_`!*@AXA9]'AEP:Z=/JGN
M'[.GC*@CX@9_WVX.Y_\`R>X>_P`?_F7="@W$8-HFLD<KN=$Q%4S@52Y)Y5,1
M*<!`#I*2!DU"#IQ*8!`0X"&E!,U`H%`H%`H%`H%`H%!*=^_F+>GZ)W'^1WE=
ME7?$+!MT&BH1CRE/FI>6-V"?[1FS7^9EB#X/N=JU8\0WV_6WXY,^WEU'JG5;
M'MT.%2J;C7^)%]&F_=RV&_"YSQ7G3WZNNE_,:T^F2J</OLGZ$&CB>HQ65B[E
M`H%`H%`H%`H%!M+?@?7"@XVAM=-->`:<>YKY_101T'IT#3N:]''3S:#5Z+AW
M-`\SCT<.GNT$0#SPX@.G#3AIPZ>[0:@^Q0*#6!1'IZ-.G_<-!$1*0.&FOU!Q
M[U!LF7`.[]C4/]M!PU792<1-H&O3W.]WZ#K%Y9),=`-S&XZ`40$1X<--!'4:
M"3IW(MNV\059J7819"_A>&N"I&#7H#J@$RP\>`:%Z:"BD3NJLR[Y>6@L=1EQ
M7_(P*Q6DN:&9^+F3!X<-2(N',OX,.AP#@8I.4>X-!O2M];H)%10EFXAQ['%`
M`%,]\Y#5!R'-H)3J,8)FX%,O+Q`!-KI02RH7?W(J"5`VVNWDQ`1ZT5+NFQ*.
MO]6)#)H_@ATC0;![:[040$R>2]N29Q$=$ALJXS)%#N>C!V"@T'-:([_HQ$WA
MCK;;<RY%-2]0C=T&59(>X/,5?JE`^N%!RD,E;TH5V0MQ[<\>W+&E,4%G=C92
M!%X<O=418W!'HAJ'I1/TT';2F[0UH=7^L'`V=+82,J5)9Y'6B2\H]L)@$154
M<VZ[<J&;%TXG!,?.H*LV)N`PUDH44+2O^WW4JOT6^_=>)+E24U#F17MZ8!E+
MD5((Z"'4B&O105?$HAQ#B'W>]I]F@VQ`W2(!J'<X_<[X4$-3#PT#O^<(Z\>G
MIH("!A$.''S/Z>-!#S1`=>[KT>9YM`Y3=/U]=:#1Q\SN:??H(B`@.@_5WM*"
M`Z^9W>_Q[U!`.;N^;KT>;IIQH-1=1.4..G,7B'`==:#L*!0*!0*!0*!0*!0*
M"4[]_,6]/T3N/\CO*[*N^(6#;H-%0C'E*?-2\L;L$_VC-FO\S+$'P?<[5JQX
MAOM^MOQR9]O+J/5.JV/;H<*E4W&O\2+Z--^[EL-^%SGBO.GOU==+^8UI],E4
MX??9/T(-'$]1BLK%W*!0*!0*!0*!0*"!@U#3SONA0;7+IJ`=S3@'=$?K!H%!
MJ`G?Z1Z.`\._0.7O=.G2(!R_?XZ4&KEX=''0.G73[710.7@`='0/U_K4&KHH
M-HZH%[H>;T?TT'6K.0#CKQ^MW_-&@Z)W*D*!BIB)U!'0I2E$XCIQ$>&H\N@=
M/0%!:9FK=?8.)GD/`+*2%[Y`N=\BPMG&UED3DKD?*J'ZL7TEJ8&UO0#8Y1%9
MZZ$B9``=.8>%!:7N2W`98B&^/(Q$\A9]OW=+K)W[)61&O+CG8>+*W,=*#B7;
M9N<X.G"Y03</`!,")CJF`B-!.MF)N<A6<V<V/:]X7)<#YFDLDK=T8[MVWXDZ
M9NK;+W!(2R2DL]<)Z`<Z2)1%0`Z2B.M!63'.*I+%%OR:+^9<SMYW&Y7EKBNX
M\>1HU-*N0$J+&*:$_JX6-#T*")SB;AJ(ZC05[Q6$B:,*TE494[PKASUK]XBF
M!WH`<0(NHH14_()P'@770`#A05S23!,@%#O!]P`\[N4'(*7H'S_J&@WR@`Z]
M(>=T>=Q[M!J$H#KP#S//[G#3OT$=.(::Z`'?^QPH*57M@W$>17'AEY8]MB:D
M@`.KFE(U%K.H&+S"FHA-,@;2:2B0FU*(*Z@-!3Y#"5[6$!U</Y4G6;;T/5VA
MD=1Q>UL\I0_J&CMPJE/Q11`-`ZM<X%#N#0=VCF*2M9=A&9BM)S9JSKF3+=L2
MJ><L%5<@`(BO+I)INH3KM=0*[3*4.CG'IH*U1LC&S+)O)P\@RDXYV0%6SY@Y
M2=M%TS=!DG"!U$E`[G`1XT'.Y0[HZ#T?7Z0X^:%!IT\_AT^9]>@::@(^:&OU
M^&M!#E`!Z`^QW._W.F@ARAIYFO=Z=..GG4$.4O>^KCW>F@<H=X/J\\1XT$0*
M`F*/>$/N^?PTH.30*!0*!0*!0*!0*!02G?OYBWI^B=Q_D=Y795WQ"P;=!HJ$
M8\I3YJ7EC=@G^T9LU_F98@^#[G:M6/$-]OUM^.3/MY=1ZIU6Q[=#A4JFXU_B
M1?1IOW<MAOPN<\5YT]^KKI?S&M/IDJG#[[)^A!HXGJ,5E8NY0*!0*!0*!0*!
M0*"&@4$?J'[]`H%`H.*JL`?5]WSJ#IG3TJ0:F$0^^/<#IUUXT%"LO9TQIANW
M'-TY,O>`LN#;)'4%W-/2MQ5Y-`'JTB]8N<I3"`&,!!(7NC08F=WVY%6^[6BF
MUM9ON[%ML/UVSV*4Q3)1S6Z[X\)*FM'1B<NNDNX6:O4C\PD;E*4$A$RA@`*"
MP^]\HW1@%.X[WM"ZK/DS#99GTO<SB*<7S<D6HS2YDR7/=KYVDB]7*L;D!LW,
M9(BQ^4`UH+\;6W-N["VTX[S/F44U[IO1O`1T/;$.S&(>79=ETG*%M0C6.="<
MT2H[(<BCPPZE;D`Q@[@4%T-BIWADEF#J_ELB35P/6(H%@<>2;NTL<6:JARNC
M1Z+AN9"4G70Z@B=RH8QUM#:%*%!R\3+C-9^E;8M!W=*S*SX#K<A-4K@D)RPF
MD[("8K2VE22"[I%.=01*58W4'`Q#"(&[U!D0M\R@E3:LT"E4+JK('4`1!J)1
M%/P<H]!EQ$O'N`6@[V0N&WX4RQ9J>A8@$$TU5!E)1DP`B9P$`5,+I=("D$P"
M'-P#6@D-?/&$&:W5.<QXM0$A1`05ORV"B!P-H)3<TF!0$`#HUUH.YB<P8EG#
M`2$R?CR64.8`!.-O2W7IS"(]`$;R2AA$?,"@J&FLDLF59%1-9(Y>8BB1RJ)G
M*(:@8AR")3`(=X:#6`B(`(AH(]R@C0*#8<-F[MNJU=H(NFJZ9DEV[A(BR"R1
M@T,FJDH4Q%"&#I`0$!H+<I?!4G:CYQ<N!+D+CV65$ZSRRWR:TAC&>5-S&.#F
MWR'`T$[7..HN6/(8!'42#05`LW(CJ4>GM>](1>TKU9-T/"FI^=2WYA10GXUS
M:LPH!22;3G`?0&Y5R!P,7I&@JGI]7VON4$.4H<._YH\?MT$!`=0'HTX:=/``
M'3AWZ"'+YF@@(:Z#]?AJ(:4$>7CT<.[W?-U#CKKK0:1*/0`='F:=(](#J.M!
M$I=-..@](APTX>90;E`H%`H%`H%`H%`H%!*=^_F+>GZ)W'^1WE=E7?$+!MT&
MBH1CRE/FI>6-V"?[1FS7^9EB#X/N=JU8\0WV_6WXY,^WEU'JG5;'MT.%2J;C
M7^)%]&F_=RV&_"YSQ7G3WZNNE_,:T^F2J</OLGZ$&CB>HQ65B[E`H%`H%`H%
M`H%`H%`H%`H.*LJ`!IKH'GZ#W/.[]!T#UZ"11,(_6$=/-'I'C06,;J=X%K[?
MFMNQ01[JZ[\O)T\:V];#!P@B5JBQ;BY=STXNJ<I6<0V(7E+QYE51`A:#"7N'
MN1YO+=1CZ%NAO+1DS"H)7E<]FLU7UF6;;K*1YI*R`DG_`%B4E?,J*0IK';E*
MW:)B(F,)M`$+2\Q8WON[<A6_*8[BXB2&WH)S9S:/N*X5XN'@2+`EX&XB&#)D
MNLJ]<+)$(LH0P:H@*8`'-K07<-[#MLYK(9[NKTMYI&XG0@E"X.PI9,Y/0Q)A
MX9-=DYR&A"MY.4FI`[H`5;HR!T4$Q$#"36@O*=J8BW5@\Q?;S^ZK45:J1DK;
M4@E#N("](,@AX,WGH9I/1_5$;."@*)S)D$$N@#%&@NIEMK,7CNV!E<G[LLQ,
MX=W'0<%%0"T\P@4I23B"F,V:,$8AL65DI&:3,*+@J.JRP&U'0:"Y?$][XVM2
MSHF/QQB&^K=M8XG7.+>S'34XO^<2/'DD1V?QJ]?'5*)CJ+<RIOM4%(<MWL^G
M9>2:6=>4]"-EP))L58L5&[=XHLF+=_'R;%0B;IL_8OD#@<@Z&`#`/=H,/^YS
M'TM<\NC(3;B3DBOXE9LY,N_D3E5,R<&.!CD.X$O,<%.C@`!089\P87@6UN3Q
MDD!072N1NX(F&NAQ%N8@(E,.H]880UT`>B@M$9VFK#PLY.(G?-C-FZR*:D>Y
M>L^I4.JFFG^,;+I&!4#=X=:"H6.<Y;B+)8.Y*S,\Y:M>.BR*')'L;XG@;F%)
M/\7U:#MVX3TZTP`&G`!"@O\`,!]M+O\`\6H$BYJ];?S/"M3IE!+)<&#B8(GR
M\PE&XH@S*15*1(HB(J".G309N-KG;Z[<<J+0]JY[MZ9P/>+T#(J3BO67%CAT
MY`P`11.;:)C(Q";@NIM'*`D2`-#*=V@SAV3?UDY*MQA=V/[LM^]+8DTP48SU
MLRS*8BW)1TX$=LEEDN<NOHBB(&+W0"@FT!`0U`=0H(T'!D(UC*(]0_;).$RF
MYTQ.4!.BH'X*J"GX:*I>X8H@(4'31X24*JA&O%',LQ64.1I)F#G<M0`!.5&3
M-J`'+QY2*@''30P=V@F>@4#ZWGT"@4$-.[W?J^\-!&@4"@4"@4"@4"@4"@E.
M_?S%O3]$[C_([RNRKOB%@VZ#14(QY2GS4O+&[!/]HS9K_,RQ!\'W.U:L>(;[
M?K;\<F?;RZCU3JMCVZ'"I5-QK_$B^C3?NY;#?A<YXKSI[]772_F-:?3)5.'W
MV3]"#1Q/48K*Q=R@4"@4"@4"@4"@4"@4"@V55`*'3]@:#HGCH"%,;7AQZ![_
M`-H*"UK/>=K8Q);CV5GY($%DF[A=I'M$3OIF2%%(3>!PT>307C];H(43%*`\
M3#W*#`EE6_<4[I65L9;R;%EB;+N*62AK9M^[7JK&94F$)1:+8L'(PSE4RJKY
MZD*BJ9A,B@0HG,4!"@ES=3:GJ.P5=%_6*$C.83LB"B+2$V/WCZSK2E[Y?.4V
M,/95D1C1S&+72W\;KE!VN;K%G(ZB&FFE!U5PC?6VO;WAFY;CM4\#EW+#RV[%
M:NFK5Y/1F-3RJ`/+IN=_X;UYS/X.$YDV9W!N5-X8IC"/+09$F=Q6]";6YQ1_
M+6+M1P,B*K61NB:EFSG)U\W`@!%I*8NV7%PM*/9J<*)C%03(L_<**D*`$3Y:
M#M.RLVZY"78Y8W$Y"87':T)D*Z42[?+0NU!5&=B\;Q:2:1;MEF;P5',8KD+E
M!P#40+U28@?E`PA079[;X^1RYGS/V6,O(,W$[C>^76.\06H\>M7;:PK&BDB]
M;/)0G6JEC[@N-Z)SJ/52E6.D4`(($H+K):1]3,_)P[J455;7LBYD;29H`<JY
MIQ-+E>QK14G,0P+D$JX:B`B/,-!2>[L<W"RM^SIA\@U?3:+M1G=*J2)3+KH/
MA`S=^H;0"G=-2H@0YNDPFH*)YOVY$?,H!R1SUK>:EC1FI4AYFQI)J==`_#@!
M2G1T$*#%MG+9HO%H2\4ZC1.NLY2E.L%$>19-L0W.=(Q@Y.<_.&H%#4._08M;
MPP1*-8LL&@P20;FD%SK=:F8K(PIKBY`#Z@41.'``-YM!3:Y,)E860V)<#5M'
M%?OQ1BE&OX9W@&%P[!?30.H*(%*4./"@MZN2SG%GL!MQ\+,LZJU,[52:J`KX
M<P?&`4U$ER!^(=)-0!,Z0\2@:@D$;<5BT5&C8IBR[_5FX;*-0%1HW5ZLRW4D
M.;0Q5"G*F4^OHC<P4%V^!LK[A]D:B%Z8DR6XM23D'17"V,G,F9[:US#Z$KM[
M,VN?K(M5@U*'5K+)BFL580*!^%!]-^Q;MB\5[C'<7B[.#!AA+-O@B!"E>/TP
MQ]>#LQN36VYIV<@QSMP42G!HZ$!XCR'-H`4&:(ARJ%`Y!`Q3`!BF*(&*8I@Y
MBF*8!$#%,4==0X4&N@4"@4"@4"@4"@4"@4"@4"@4"@4"@E._?S%O3]$[C_([
MRNRKOB%@VZ#14(QY2GS4O+&[!/\`:,V:_P`S+$'P?<[5JQXAOM^MOQR9]O+J
M/5.JV/;H<*E4W&O\2+Z--^[EL-^%SGBO.GOU==+^8UI],E4X??9/T(-'$]1B
MLK%W*!0*!0*!0*!0*!0*!00$=`UH.I<K`&O$?L^=Y_=H*-Y)R'"63#NW\BL=
M9R1A*/F40U*95_*!%-#NW*;9$GHA`H$`!..A`,8`UH/G^R;N%ELJV;-D390E
MPYOO.XDEL6V<JY<2C"W&#XZT?(7)?(Q2BRD):UF1)A,BD84S/9,>70W+048N
M7:U>L[:F++`Q`>!87)CZ9:O!3NIG*GCUF4L15O=4RWCH[JUUY.37<K*%ZS4J
M93\!`P:T%W%L8@FH2]K#C,EPUZ;N,BXL;JH6+@'`T3'VMM^P>D*9'+2Z<CS-
MRR`P[G*<B4P*)G>JK/42FU31)P&@O[@K5Q5O*Q]EC!.8[%8)N(Y]%'O&R(6_
M&LE+P#HHE=M&Y;@@BM7D'/1ZB1>M*``FMKQYBB-!*-Q;<]DVW>XK8]3VWQ;,
M6<;F;HJ6?C]8B]USCA>,`&ZEXRD?<#MQ;=I-VX`1-U-+I)B8"%*43B`!05^M
MR[]ZT=/F4OBP=OUJXZ;@S.S20O.YWDV@P/Z%6-<2HL4XE&1CTB@`&%$$%!T`
MIM*"Y/Q#;\$_D;Y9VVQ:.+M;,4[U-'LFAW<B5-/JFTD^<M2@9_X$DIRG.(F$
M4>/<H.SGV<:$:U1B@;^-8DI)B"2(F5RJ46Y1,!$N;F,FD[0$R6H"'`W"@X\S
M)M;CLAV_2=(QZ;B.\-;O':Z;=!H]:Z."INSJF*5$J#E'E4`PZ@&NM!;_`']N
M0P-ZE6!)/(UN+OFJL3)@SA%C2ZH/&;A,KE!$L>14`,(\X`&H<!H*4Y$W([>;
MU?Q)'I;H<MC,9)H5=I;#D1YU4TQ1`G/R&,9/3CPX!06G7EC+#^20?-X*X#1J
MHIMUXY*XHIS#.E7H*<W*!54@27`@!Q`IO1A06,Y>P-=ZP'6;VPG<UM)*`=29
MCC((1I6S,1!X,>0#*:.W2B8$.;0!#4:#&K,86NZ0R2>8E;3-$,FZ(*Q44]7Y
MD5BK<Q6P.'!0$R:Z10`XE4TY@*'"@U6[8X6?.35_7+$VU)P1FJD4X2?+*N9J
M&>1*BRCE\T;%1$CA=P*Q$T2E#3F'4>`4%&KK\:W+/KA;AXYXRD3J7'$PJ*Z+
MOQ?!=2*2T&(&*8S46ZIA.JD<`#G#F'4=!H*=7.,5!I()JQ;-W.JE;]6QE#\S
ME[(-U5'"3M7D%)6/A&Z0@*#?4#KJ%`PB!0`*#-SV8G:SWABOQ'@W=7).YW&2
MJB+*T\K23H[J=L`7BX^#L+U76/R*V<D!BI-5@$SAN&@"`IA0?5S%RD=-QK&8
MB'[24BI-H@_CI*/<).F3YDZ3*LV=M'*)CI+H+HG`Q3%$0$!U"@Y]`H%`H%`H
M%`H%`H%`H%`H%`H%`H)3OW\Q;T_1.X_R.\KLJ[XA8-N@T5",>4I\U+RQNP3_
M`&C-FO\`,RQ!\'W.U:L>(;[?K;\<F?;RZCU3JMCVZ'"I5-QK_$B^C3?NY;#?
MA<YXKSI[]772_F-:?3)5.'WV3]"#1Q/48K*Q=R@4"@4"@4"@4"@4"@4'%74T
M#AT?5K02V]<<H".O=#33B(B.@``!KQ,(CPH,7&ZW,^/K:D9G'\W=*LOE'(#.
M4A8>V86+<.&=KVK'HE<OHF2F2<K)A+R95.L<%ZPRQP$"@4-*"P6TL"LL=8VO
M%CA:`8X[O)R_C[;0C+89LEKEOR[+J3%^C;MJ2KH7CX0M]HL+B3<#S"@=0"E$
M@:C03ILL+D7'D!O+DBMQR2^VYG?GQS>#.<?70>>R,M:PO9NT'4DY=.$I5:V9
MMP0JJ::A4"JD$F@:#09,\$SEF6EMPQ]>;VY8.Q[<E(5&\<GW3,KQC12]K^F4
M`=74,RJW=*.CR!9OG3T1.LN($(D4.4`"@U[0(>2N+)FX'<=+VNM8L-FF<MN*
MQS"248G#RDI9MEQR[-O=+]`I""9:Y73DRR0J@5<R(%Y@Z*#A8=C65L[G]W5[
MY!N6';Y#F7=G#;28G=O%K7PU%L4V4"RD0%$S=BSEIXZJYB)&YCF'G,/#@%QE
MR7-!W1:\YC**?+W?<=R,)*,=H-W9'H,&$OUK9Q+&E&Y"-B,8T%]4P*;K2"4H
M"&H:T$ZV1'J6';UOX[EWKF63B(5G$14\_'G/-(LVQ&P-'RIQT-*`0N@A_P`T
MG'IUH,:V=]^UD[99RX<3X^;ERWEZ4>N7$-#L7@NF-E++FY?$=UR'.<2C'F]&
M@U2'FZK0IM!"@L</>^8+S>/)S<ODHUN>/VZLQ:^++31=D<33HZVCB*B+(8**
M+N55@."HG7$I3<1U$*"8K3LK([UM<MIV+C8ELC$&-+PTA,P1Y^Z'X22/AK9D
M5ESMXR-`BA1`.8QQ+^"/$*#(_8F'9*<+C96[H>/&0G8%U)NUVR!6J17*;1N1
M5)XV*'5LGA%2")R)F,00X!05_?X7@TTWTH5JQ>"T<B@DU>H`BD44D2-D3L5$
M@.*0F54UY3!I02],8#@C^`1)&R<0$@9-62,W6,9'P1,@'<I@@0!0`Z[C0H"8
MH!TB-!:=E_9/ZH82XWME@@X!(5RJ1;A04QDW!0$5SQ+PY0!%PVX`F'$@FZ.]
M088,KX)N-NV<0<:I*-Y=@9QU<=<8F*BTE45BF7(Y;I-T1,3P0HE%58QA$PZZ
M:#06*7I#LK&,Y+%1H-KP7;E:2B:Q45F[70PG646ZG3J&YBAS-4==3_AGX``4
M%LDG;:0**3%SO72Q71CND4R*@>9?F$#!S-#*@H9)'4``S@P<A`#0H4$CN33]
MPK1[1JW,BBF(L6$8U2.JBJ`"8$3+)::R[]0FO6*_^B%!]&'9#[Z[KP])6[MA
MS_=";O'=UJ]1B2?F72KF7LZ9<N"MT;5DW>IVC>VY%V`I,TA,)FBWH1$"FH/J
M;#O:B.G?^S]^@C0*!0*!0*!0*!0*!0*!0*!0*!02G?OYBWI^B=Q_D=Y795WQ
M"P;=!HJ$8\I3YJ7EC=@G^T9LU_F98@^#[G:M6/$-]OUM^.3/MY=1ZIU6Q[=#
MA4JFXU_B1?1IOW<MAOPN<\5YT]^KKI?S&M/IDJG#[[)^A!HXGJ,5E8NY0*!0
M*!0*!0*!0*!00$=`U_VT'5.CZ:ATZ:!]S[.@T%!,QY0AL:6G<<W(2:+%W&0Y
MWC,QT1<G2=.E"L8\Y6VOX]4[I31-,.)S%[U!@XS3'0]UYGQ$VC$'#IQ;JBF<
M[T=O9A)5Q;LB_;FA+4M:0ATS>$MI6[7:AY)QUWX30`*`:!04LPE!;OX+<5<N
M/\48>O3]8`#/+6MGC*3YG,8BM&/O0YW$_D1C$L0(O**(-%_`V$<02K`HD7KC
M\H4&;C:E;VUK!MCL=K.,<B65=UP,EYV1R%%M))G-2ERWK<[E=]>\S<!&)G*#
M%S+RSE80;JF#JD]$P`>6@U7];&U[95AU-8V/X]Q;_JT(ACO'[K2;*^R#><D(
MQ=NVHVF/"D(U)W*+"8!Y13:DYC]`:4$\69;>Z:73>W5E7(UDVC&G;@_B\:8\
MLYI-I0C8B?6^+I6ZI]4SB6>()EY14:IH)ZZ\G#2@KA#HPLNS:7C"H15SHR$0
M1MX>FW0\8/&I1-UK3PLP:NFY%0,`-UQ$$S\`TH.K"?M5U(*VC9\6T&>8I)/9
M5FP02B5;8(YT.W<2@(I$.W6<"&I$]!ZT`UXA08M]]V]B]+3D4]L^)QBYC)TT
MD1M<U[1Q"KIVPVD#';HQL8W$1!G>ADC@;F$=$=0,&@C08]8K`[JQIM7%3%@Z
MF-S5R1[2Z7=V'<(R!;!8O#@Z;R,L@<#.7V0'Z9A.BU,;4"?C3`(:!09.L'[.
MHU.U`GKY.^2RO:<BQF2-)"82<W0^EVP=<G)7!/B(KJM9]N8W@S1/JT6X&Y1`
M1"@R"VY:-LPEP0UX1K=5L[NF(""?*.%C.SKF3*+IDV.IS"FBHV<"J34H`)PH
M)GB2H%5M(B!2%!DYGF/*4I@!(Z0&!0A=1U+Q^S0=N1T#@L8V*CS!)2;MT<J@
MAHFV:&,90Y@U$.)@#2@WC""IG#I#K#NI=3Q>U.(:]0R2U*HL0!_!3XF,/?-I
M0;K6+2`$&Z)S&B8\=4TE!$PK.2F$PJ=9P`Z*9A$=.@3\>Y06B[I]O#;)T5(7
MQ:C5!.ZXUD=)\`!RIW`Q:IJ'-U:9``JK]L`B!#B/XS3E[@4'SG91P"V&;E2,
MWZ$C=<J0[XD+),G`%.[8<3J.#%`.O<HI&`O5B/*74-:"W)7:@[<G?75.)2RS
MJ/D&"A$SM%A!XS<MR%=,63`1**R#!8QN?CU($XZ4&[+;6KH%\LVB&1H*VXYH
MG+EE/!SJO7J3D@E-'H.2`599(H"/,F04DB`/$U!<7:&)K`&%<6@V7=MKO1@E
M9*/3,S2"4,LX(50A;;?N$Q;-NL53T`R'.HW.//S<P:T&?+LZ=R3[+F.7F-KV
M*LRR/B8&<`_;R<L25EY&&20`C!R]>&-UC^29)D!-TL&H',)3=T:#([0*!0*!
M0*!0*!0*!0*!0*!0*!02G?OYBWI^B=Q_D=Y795WQ"P;=!HJ$8\I3YJ7EC=@G
M^T9LU_F98@^#[G:M6/$-]OUM^.3/MY=1ZIU6Q[=#A4JFXU_B1?1IOW<MAOPN
M<\5YT]^KKI?S&M/IDJG#[[)^A!HXGJ,5E8NY0*!0*!0*!0*!0*!0:%!T*/U=
M%!T#TX``CKH`!J(][3I'IZ-/M4&/G<7%'R-CV\(R0DW]JNIR90-;$[`J,AGX
M1G`F,1E,,DWJ+A!1V9P)C@51,Q`\^@QU1^*<D8SA)B9QEC4V3@;3*$OD;)>4
MY%=W<%U+Q;49*<3BF2`-WUU3[2+2Y2&$46;'4I$BB'"@NVC+LN3.UMXUL[#J
MC^T;-W&J`,M>K]TXC[LB,7PC()"]XZ#<-3)NXN??\GB]NH33J>8QNGC05HW!
M1]@[<=N4Z_Q'!,L.7+!W-;$7C9M'1+*)F+YN]I*LFC1F[ZGFD;P0N)%13KNO
M,=18H&4,.NHT';[A[QB[*S)M6OC,:D-'8VZV0MI^:89'?,H_,=VL6+6TR(-#
M(KD;.BKF6*FY/H"`:^BUH)SRW>1(.V[_`'&W2<4OC,]]D\"M:#1?N;JL]I*-
M"EC%CG114&"A(N.3,=1QHLF(JE]%J/"@J=@FUKZQ)B.P;/O9!K<UQLV*AKJE
MK73ZEBA+/W"KUT=O&N%.N,U35<"3\68P!RZ]`T$G93O"Q\?XWR+DE"32)=42
M+URC(-C&:3RD]RG0@XMRBH0CAXV(Y.`%14*=(2@.G#C089+"9R>,K2NW/F3;
M+>92ON_)5TTQ\=JW*+B5R/<:BB[`DRS4#PE!K%@87*JB?,D1)`0X4%:8)JOA
M^"5ELB/4,@W*59C-W3DZU'(^*;5O]VD"K9.X[E`#2-S31#G(W8M&QA0:H%Y5
M1Y>%!D)QTM-&%&4NEHU)DP\9#7`NQ\*!U#W+"NV2+F10A2K`44))D4Y5NJ.)
MC)JB/+Z$U!<,D6/39.O%B+AY%ODRW;"F16YR)OVQRJR#)L8-!;J\!,!`T*`F
M$*#FL-%7*SEMP30>N)=!,N@<WCF.*X$I]-0U(MP'3NA0=BU6.B!6H*I%.DT;
M1Z9SEU4!V[U=O#!H&GXA`=!TZ!TH.X0)UYS&`3I&,B"(<X\O@D<01_&%T`"E
M7=Z<PCTZ4&ZJJFHFD0HG2CP$$D2)`;KGQP#@1(`#FZH1Z1'3F[]!NZEYDQ62
M$RY"<S:+2$IBI%Z"G5``ZOK-?^(>!>Y06#9QVUV^I<<Y?3%J)9.XE".TT&[9
M)R,4[('_`(B5FKRAU1'P:&4(4`*.G=H+$\A8PE;-EXJX65KS=[R:K=*,+!MI
M5&,!A'BLHLXGNK>J%8.5404T.F)0$R?=X`%!2R>L6YKBEW-N,50>(MS)7"S>
MI2J*,6C"1Q!=2C1--/1$DD8BH)`@Z5+S"4>4HB.E!-ECX"@SRDA?`(/#&,,8
MX.^F%"(FBU%6)B$1M\Y2^%H-5$?PP*'5E4Z>`T%QEMQ%H8$NBV\QQ+YI#J%<
M,FUQ=05-RC.L9E9..>'DSLDP<+2!P$OXP2\!+Q[]!F4:N47K9N\;'*JW=().
M$%"B`E.DL0JB9P$.`@8A@&@WZ!0*!0*!0*!0*!0*!0*!0*!02G?OYBWI^B=Q
M_D=Y795WQ"P;=!HJ$8\I3YJ7EC=@G^T9LU_F98@^#[G:M6/$-]OUM^.3/MY=
M1ZIU6Q[=#A4JFXU_B1?1IOW<MAOPN<\5YT]^KKI?S&M/IDJG#[[)^A!HXGJ,
M5E8NY0*!0*!0*!0*!0*!0;*WX/U=\*"1+L=F90TDX(<"G(U.5/@(^C.7D#0`
M'41XC08\[IMHGZV+`E6T@X=7)/1]R-!AG`.G*,K$1K,KI,$D%/[(S0CY(2@4
MQ0`Z@FXB(4&P&;;;C,-O(J!60O7)I6<GBF&QM;;]*9FU<FWBZ>HRBTDF@!RM
M#P3-R*KE4Y@(BV3Y1'6@K/,;>LF8_P`38;9[?75G,\EX88L$6[:]&)EX2[8E
MTS`+OM=.10U6MIQ.NSFT?$(H)-.("'0''N3#TA=<A8F>=Y%[6Q%PN&B$OJ+Q
MI!$(UQQ9=Y)MSD4N.8N)^925NQY$H&Y&P&!-$#B)BIB(@%!<;`7GA;<3:1SQ
MRL%D"T':I#IEEHA88]THCJ=%ZR2FF3<YS):\R:Z0`)1XE,`T'")&6%B5K:^/
ML:0T;;KV54?)VW:L#U#*/!,3G=R<J^1Y5#':MCJ"HH81U.<=-=1&@FZ,89`B
M.M"4G8R["'`ZA>L8E@G"9Q$1*B46PJMCHD`>7F$H''I&@Q[;[7:%WPMG6E+6
MM(QBSB5--R#]L45U!"+$J319L_BS"X<D1,H8X`H74HAT4%NERO9UEE#!5N6S
M(-;SLRT\2S=XRB#IVW8O[9NR<$8I*<>N")ZK.R,43$3(LF)R%,<>[039"M8=
MC<%_73>[B)M&)LP]JP%IXQ>-U?4H9:<22<RU]WBD<#QKB9F#+<S-8AA4Y0*/
M+KPH+XL56#;$7(O9>)AW#!]<)6<PH1[).I<QWS$3MVD[:4@Z4.W2;G::<[8!
M+SD'0Q0H*^M2B@B)3I)-UD'0O44F&I6RK\!$JIVZ8ARHH2!!$JJ)@`"*^8(4
M$QI`AH5<B74D7;)<B92"02E`QPT,70`YT^82Z=S2@V1;F4<&_LY!Y#'!/F,)
M3**K\HN#E'I`O(4"B;O4';'(()]7KJEJ!EA'4.M-H&G6#P$&Q.@"!Q,`4&Z1
M)43"9,!(;\$5C$`3]6```$;)<"MTQ[X\>%!R4V0%#03'*40]%Z,3*J&$1$3*
MK#Z(PAW@X4'2W4P%:$<"W%1,S,IG0`BB5RN<J29^8B*2FH*K&`?0E$=#&X#0
M6?ST+<.DPHXM^9OF#(NT0.U8%B4KPL]%U'F=NI!LS(FD+U<IN7G:&5_`.(E'
M4-*"1('"%N(R*R#6/.E$SC(\Z-JI$.U\->/#BX+-N"J>C!X^.3D.5?7JS\--
M-*#;O"SCPSN"E4(%5`S5XS6305T>@HT=J`V<,DW2*B+1NBGKS*DY#_@CT4%(
MKHQ7'W];4Q:"LK*13!"X#W,VDK>(FG(**13LSDD:1-<#BJV<G*)1#T*9RB`%
M`!H+_=LD\,EC..AEU72CVVC#'&!^)A>^!'$RS`[@#^C*H*0B40'\$2Z4%Q%`
MH%`H%`H%`H%`H%`H%`H%`H)3OW\Q;T_1.X_R.\KLJ[XA8-N@T5",>4I\U+RQ
MNP3_`&C-FO\`,RQ!\'W.U:L>(;[?K;\<F?;RZCU3JMCVZ'"I5-QK_$B^C3?N
MY;#?A<YXKSI[]772_F-:?3)5.'WV3]"#1Q/48K*Q=R@4"@4"@4"@4"@4"@V5
MOP?J[X4%)\BIN%XM%L@;JSK.>)^.A03(80$0#I`1'O#I047LZUEVT^OE_*QF
MEEQUK6^O:EIQSN517;,X]RZZ^5N5XX``3"1G%2E*BF74Y$@TTUH*AL[#Q-C%
MS<>6K&L.,5NW(:T<LZ>037JW5URSU,$F#GD/HW9K.RF`5W!2$,8@")Q&@G6"
ME[NA.K4R*X8&6FY))I'-[>8JGC(85B"9%FY>'$[IP<PCRF6.4J?,'#@-!1C(
MEFVYF/+B,/D4%'MA8=1@;M86SH]+'W!>D@*ZK1]/-TB=1,QL.U0T2:'YTA6/
MS&*.E!5.=NZSHQM`SA'Z$2R*\;1JC!RQ7:(G:OE.I!%1EX*`)+)'T$@Z!H'#
MHH./,-<1R5SQMP2+R$1G"1[B$CY`CU>.D4D7!R+*MFZZ1T#$*H!=1X@-!S6Q
M[9BE7AHS(*Z@N#`9*/=W"TDD$5"IE(!&Y7/6N"%'340YAXT%H>;8B:+?MLO#
M7E$N6J$:H+)*68-UVH/'+@QQ3\,:.2.`X:``<@AI06<7I<8S&X7+EM25J6!(
M-H''EB%DW4G-O(EA).",5USO$YA($5HQBT8NSG,0H\QQ1'NC0:+'GFMRK2D.
M[0G<TL%6D,=H[LF/;2MI1:S%T96"+)J3;MNI/QL6'_NQECF4+IQU`-*#)#8$
MF\@8*(M-KS0P$9(J&*_;'>$2`ZACK`W;J!X,V$X")0!%70-=2AP"@N%21:NV
MZ0`L(E%N4@*F4.8#*:<0.;T)C*EUZ1T'3OT&VQEXN(<%A)B2:-'+DX*1R#MT
MF0[@IC>BZ@5#@<X&4`/0CQ"@G8J>H\P:B(])N&@AIW.G2@W@2(&G#HT`/,TU
MZ/L^?0;NFG100$0`!$>`=W7H^O0:5`*9,X&XE$HZ^=I0=4WAV#59\Y;MR(KR
MIRJ/%DBZ'7.5$$BK+#TBH5(.4#=P-*"W68C)"&GG,;%RD^_0-SLRF*HBHHP0
M43-U:2KERF"@II++%$!`^HB`:=Z@D^>QKFQ!I!2[6YK2&0.[9,):$G6:?@:S
M,CQ,H-VC],ICM',@S`PK+$`RHJ"!=-!$:#<1PG=<?+PJY[BBFKF6\=*.&;TZ
MYUT'CE<QTV449J!T'+2/C2E#14``0'4-#!03'@^(O:UKPN6'NR#>.GSI-0TG
M>#)@>,M9ZDS6$+>)&H+*J&4=&C3B5P)?^8&H\1H+JZ!0*!0*!0*!0*!0*!0*
M!0*!02G?OYBWI^B=Q_D=Y795WQ"P;=!HJ$8\I3YJ7EC=@G^T9LU_F98@^#[G
M:M6/$-]OUM^.3/MY=1ZIU6Q[=#A4JFXU_B1?1IOW<MAOPN<\5YT]^KKI?S&M
M/IDJG#[[)^A!HXGJ,5E8NY0*!0*!0*!0*!0*!0:%`U*/U>9]^@D:Y6Y5"$7,
M4A@9@=?10=":#H!@'O\`H>CN4$LS5H0=YOFXSQ%7\6Q;,V<;$&+US))[(@55
M22<-P_%*N4D2<A%#:@D'$.-!U6/8_P`3L)6.<R#AS"VUD.4;0RT@X.Y408"5
M,&[7PA01,8C1=8Q2=PH<`H*LS")W9&S`G7'\)>)+*JE`.1!NB<%#"8W```W*
M`%[HB-!Q7<:_;3J<U'%051<H%:S+0X"#E=-$!\#5:*B;JTQ;F.83%$/1@/30
M=JHP%RY,H[,@X9Z$,DS59HGY%0#BH=0X',8P#T=Z@@XAX=?07$5&KB`ZE%9D
MV4$#=&H"9,1`=.Z%!U![;@4OZJ!B2FU$0$(QKSZCH(^BZGFZ:"T[<!!`$M%N
M3,(TD<@T(J?KVH$,FHBL<%`25*4O*=0A@^Q06#YI@K=OV<E+%<2T7:C6^,=(
MW)=UQ),4E'9;%QZ[6--':+<A5?&A6KDJ":93")S*%U`0H)$QE=&'+4;8;B+3
M9S,3B:^XZ<4M29?^$/)B,N2VG*I%5LBMV0)G>,%HXH&*4!*1MS!P&@O+MO<?
M:%K7O;..ID8;QO>9SKVG*&A)!A$RC,%"H-$W*RRY%6BKH0,9(3D`#<*#(P#2
M*9H$>.6R2)!2*NLJF)^H3,8H"!S%*80`@";ITX4$C3V(+*NR<@[O>,P"9AU>
ML:OB++G`R(B!P*"9U11#40#0VFNE!5U,0T`A1,!0``*81#B`!P[NO0'F4&KK
M=1'00$`'37O_`&Z"(',/<`.&NGU#0;2Y>N163YA*"B8DU#I`3!RZDX].HT&\
M!2IH@4P^A(F!1,(ZCH4N@B(\-1T"@Z<&TR,@_<`\8&8':-TXI'P54'+9P&HN
M5'2P*<JZ*O#E*!2B6@WI&/7=(E,V<^#/$4EA1'E`S-1T=$2(G>M]-7""*NAP
M+J'$.F@XB<9*"Q8%</62DJ"C)27>E8@*#T6Y1*MX,U54.5H*G_"("(E"@VI*
MV$Y9N^;.I69(5V];O$56CSP5U'=0=)3P9@Y33ZQ!LL*6BA0'4Y1$!'0:#MTV
MJI)!PZ$4>I6013`H%/U_.F(ZB<XG$@DT'@```]^@Y]`H%`H%`H%`H%`H%`H%
M`H%`H)3OW\Q;T_1.X_R.\KLJ[XA8-N@T5",>4I\U+RQNP3_:,V:_S,L0?!]S
MM6K'B&^WZV_')GV\NH]4ZK8]NAPJ53<:_P`2+Z--^[EL-^%SGBO.GOU==+^8
MUI],E4X??9/T(-'$]1BLK%W*!0*!0*!0*!0*!0*`(:\!H.CDF7A"+A'E*/7-
MU4]#@)B")@TT$.Z`T$FR4?>C*0C$;::Q(Q3Z-.SF)!RL<DC$OTV_4L7[-J?^
MSNFR!##S)Z@83`'<H)EM*UFMJV^T@BKJR0IBJN^?O0*=Q)2#I4SAV]<%T$@*
M+KF$=`X%```.B@FD`````X`'``\P*!02?<U]VU:9FS>4?"I*/SBE&0<>D=_-
MR2P%$_5,XYN!ES:@'X1N5,.Z8*"E\K*WG)(-KLO"XD<-V*S;JN'<(91@O=4B
M<P&*B65EU07:18%)Z(&S0BJYC&T$P&#2@DIY;6,GK!H_0@\R7`W?AX6E)QTM
M>W7*D.(&(X$WC5JHF14!YBE`I0`.X%!3/(ZEDQ<$\MJ/N:ZV,VHT.ZB[=OYS
M(BHX3/H*GBY_+IJ*.7``42@EX08_>+W:"RZ\V'A=HPMXILE'\A8LRDRDDT62
MCQ<F-Y9RV3O`HMTOQCU-N1,JYB@`F+U6O'0:#ILA/H'$TE83>T;9>9%M9*6G
M+WMUS:D1XV1QG9LTS*HO,7&U*EX/<P.G@@L#4#`*:!!`0UX4$H9.:W'D.V\7
M24U<D5=UYW#>R+F%RI8,*50UJXX<+)IKO3-"D\6IN&J)C=40P"HW.`@8.8*"
MMF(I/.]J7G.8,)E^85191\5)6'`WC'MY<E[1*+M0TDF>[W:WAS-6XVY0,V5`
M3I(F$2"``&E!E0)=$HA9<-)/&/BB2,=)"2B),2D6(X%)5/Q:"B.J)E3+E*0%
M"^A,7C0=Y"W(5_&,5W_)$O'"!069=:"@-U@U*9(!'3K``0X&`1H)I%TF@F"H
MF`6Y2B)E@$.0H_\`$*G'@7S=:#4+Q($NO.L06JA!.55/B44^7B/,`CJ&G="@
MWVIT5R$%LJ11`-!**8Z@(=.@F[W&@XTVXZIN@W`%#*2#I%F0J8#S:*#S*F$0
MTY2E2(81'4*#N"E`I0*'04`*'=X`&@<1Z>%!&@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4$IW[^8MZ?HG<?Y'>5V5=\0L&W0:*A&/*4^:EY8W8)_M&;-?YF6(/@^
MYVK5CQ#?;];?CDS[>74>J=5L>W0X5*IN-?XD7T:;]W+8;\+G/%>=/?JZZ7\Q
MK3Z9*IP^^R?H0:.)ZC%96+N4"@4"@4"@4"@4"@4"@@)0$0$0XAT4$:"7'%WV
MPUF2V\XG(Y*<.9$A8DS@@/C&<(F<(%!O^&(K(D$Q>^`4$A7-E)_%(/%(.QKA
METV:)UG$K(E2M^!:$3,(**.G;T3OQ23`HB)DFR@:=V@E%S?0R;"%N:;RC;UO
M6K)H*"TCK206=2DX[3X.6C:1=)JOU!;<P``-FY5!-Q'APH.;`D2BG*##&./W
MKA9^19Z_O^\?"&R"2CO05CKN9$5+CE'BHB4QD$R)):?\0=%!SGUKVC::`7_E
M^XV,],1K<P&FKAZMM!10*K`86]O6]S*-&YC*F(4H@15RH8"\=1TH.\1RC9+I
M[&1QY=6+>3B(+PJ4Y'2$(63)H`\C)61;MT55Q)Q!+4%.7CI0=C=%OQ=T1+B/
MDF3)^DHFHHT.Z;H.BH.!3,5-VU.H53JU2".I3D$!#OT&-[&4<K!WS=]KRO.9
MQ&/Y-L5(VI.O8.CCR:E$!ZQ!1(PE,&F@ZT$HW]93AA>,;C::D)^W+/*J>Z\2
MC!RZD!!W*"2)EIZ`G)5LV4%"2MU0%%$TE@Y%VY@``UH+)9.R6EF$NBT[(R22
MUVPKNKL1LJ4GA1MRZ8M\Z$SJ2"?05*I#+22B@\BHBFW*<0`0UH.+8N1))C?&
M)K%N5[)+,H68D):,N]:;:OIN#:O54CL;+;R[91=T_BD')1.5=<2E,!M`+IQH
M,B^4+MO2$Q-(W-?&9"SC:$O."N"!A[;M[Q>Z<-EY,&<5`STH)UO"VB*C@!$4
MN7K>7T5!53"M](K8DAI&Z9-E<L:R&3=RL^WF$2>IIP#YR?P<K;J2R+?P5,W*
M*2HCIIPX4'(M#(I'-Y1:3&5NMYC^ZFSIRVN-:.<.8>3!(YTDH6+*`'.H<^@]
M8L!"%`.''IH+KO5"S8"DP:NV+=JK%*'91X&3%_&IM4S"JLNV,H8PIB70"ATB
M;ATT$U69UZL05XLF9$CM4ZK5,Y.J4!MH4"J*I="1UE`,<2]P!"@[PY2NI!$0
M4*)&)3*"F`ZF%98.4@FTXE`I`'0!Z=:#LJ!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*"4[]_,6]/T3N/\CO*[*N^(6#;H-%0C'E*?-2\L;L$_VC-FO\S+$'P?<[
M5JQXAOM^MOQR9]O+J/5.JV/;H<*E4W&O\2+Z--^[EL-^%SGBO.GOU==+^8UI
M],E4X??9/T(-'$]1BLK%W*!0*!0*!0*!0*!0*!0*!06F7V[+<\Y=,DU@(YF:
MU+BA;=@KH?+.RG4N!DU5D)>5=-&HE4<L;9;:]2CJ`.5M`,/+PH.IAL>7#=]N
MR=XRMT/;6B;B8)KKN)P#7%<,O%-%?"6$E(F5=I1,"R>B4%R1S)$I2%,4#G$V
MH4$TV"#JU8X8UNO:THS\,5D(]\^MF5@5@5=:&66-RJ2B9SKCH/,F9,-.@H4'
M.O&ZKG6N:.C[:OJ'C#3K-L1E"KM5E'IWD<<5)AY%E4:\SEJDV$1,0W$^@::<
M:";B6#"$F37#U:MY7:Y3(BWD;O>>$MH9H(=9_P"&11TRLV9`-H(@BB"IA`.8
MW"@Y4[:EU.FY'3^7C[C1;G%P[M]W"L_`72(`(JH-#JE5705Y.!3`8!H*4/W+
M7$PVI<=K+R*^.[DN5E;MQ6R[D%GR=NR%QN@9QTM">&'6=M0;RIBH+,RGZD"*
M<Q2ART%L>Z>4?8MRY`9$M:(=R!H6/:O\C<J8A%-[7?/ACR"NMT>'JB4ZJ0%`
M>"0ZZ4%VTA;UE9UQ4C')J^&Q4RR;3$!--#BW<LI%(0<1LBR=ICSIG;K@`*``
MZ'+J4P"`T&(_)]M2UH7%<=B/[88W)<`Q39&\FJT5&G73C%7!0]4#*",D1K+V
ML\1%-9=)LJ0Q#D,?EYM:"VVZXZ[8Z<MZU5+.M!G:<"`W&>^L=(+2L7+OTC)J
M*6[)MXM,DA`!X&``MJ8XE,/*&@A03?FS*D]=6,(.S<!(+.HR[KDMAU(Q#Q(Z
M,DVC;1E&TC=@VJO*#X8[81K)$YSE%(3`8N@C03K8&X2V+9W!7]<]OW9:4/;4
M[#1T:C:,TZ6!I?-T(($*K/2[!!LLE;1D1'\>`$_'`'?&@KY8>=KGM(9=&7DK
M=O:7</7+ZRK>L.74<M7[B2.856RC8[5`(*!:$4'F<&Y2@!-`XC07?V1;L=F"
MX89]U3A<(5FT=2$[%*N(Z-C%%RE47@R*I<OCI<JY1*'6";E`!,(T%\+]\PMZ
M*6<+J$;,(QF*BASFX)H-TPY0U$=3&,```=T1&@V;<(52/+)BFHFO,B625!77
MK2E7(`MTS@/X/5H<H:!T4'?T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$IW[^8
MMZ?HG<?Y'>5V5=\0L&W0:*A&/*4^:EY8W8)_M&;-?YF6(/@^YVK5CQ#?;];?
MCDS[>74>J=5L>W0X5*IN-?XD7T:;]W+8;\+G/%>=/?JZZ7\QK3Z9*IP^^R?H
M0:.)ZC%96+N4"@4"@4"@4"@4"@4"@4"@M=NRVUX^8NNU'TRI&,+^EPO"Q)LZ
M1B-(V[6[<J<M;\L[$IFW@\H0`%(J@E`Z1SE+J<`"@XUB3,M&QI\87!!OY9DD
MW7:.8<[ELG<UKLE@,HU8G*LJBG<T&(`/@;YJ8QRI\I%":A039&Y+AH)%*(=2
MB14V9S-$37%!3D"NV3(82(H.'2[$S)8R1`Y14*;0VFNM!SKF:6H_&(RA(FMQ
M5S::;CQ1<,>HO(JM3/2^#JMFR2)P2776!30A3::''4:#K)B2F[K@VRL39UR,
MCLU2.XN=*\;!)I+<1,NJQ-H9RDL41YTN?30>'<H.8DXOY:UUY*5O>WX&,8I+
M*R,P=BKX2W;H:@MX01T8B;1=/300'F$3<`UU"@IBG"LI6)9W')HS*.++#=+9
M&3>2XBE,9!N%LBJX:/"Q0`4["!9G$#H)*`"BZXD$"@`<0DFY(M>3L9_`RL.K
M<>5=Q#U28-:LO(%3"UK<53*DW6D#)<W@,#9\4)1.5,-5W9Q`/1&$0"T#:KN+
M;[<,QW/M$S`]<1C!.8*IC6>DC'&.Y'GX4>JZ5$W@S5TH/,D)C<H".E!E(RMA
M6Q<T0I&-Q-U6DD@03Q-S0R_@<PP.<O,B8CQN8AWC(!T$4CF%,P:]^@LKO#8#
M>UTO&;C]<$:F5@11)HF6V5(\Y4E$3(&!5:*<MA<JG)H<3JE4/SATT%7<&[&[
M*QG+&NZ\GK:^;X;V]+6I"SA&(QJ4'"3S;P:;%BWZU8/&<HGH51P/HN4-`#B(
MT%L=G]F/=UC7I?LW#92LM[#W/*>&Q1YRP$9*X6[?G,8C66=*JBT=^#$$"E%,
M"`<"@)@UUH+J\:[,X*TY^;N"[[C)=B\XW:MGC%I#,X-FNDW*7\2H#7F629B<
MNO4)"1/3IH+MB#;UH114&B$9`P[%$`*D@FW8,6R290]$;D!-%(A2AQ,/UQH+
M2VV3VFX?)3*R[)=>%X]MIV,M<\Z!5B(3ZD4OU8L6`Z%*XCCON4A5>)%.4PAJ
M`:T%[!2E*4"E`"E*`%*4`T`I0#0```X``!01H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H)3OW\Q;T_1.X_R.\KLJ[XA8-N@T5",>4I\U+RQNP3_:,V:_S,L0?!
M]SM6K'B&^WZV_')GV\NH]4ZK8]NAPJ53<:_Q(OHTW[N6PWX7.>*\Z>_5UTOY
MC6GTR53A]]D_0@T<3U&*RL7<H%`H%`H%`H%`H%`H%`H%!UTM$1D['N8J89-Y
M&.>)BDY:.DP515(/?*/$IBCQ`P:&*/$!`:"@UPXT?1;,C(&B]_68S,W,PB73
MM9"^K3ZLQ^L=VS=!5"/WY42F`2(*J$5*`:%.;HH.8TDY)&*5NRU;A/?UGL&G
M52EJ3C0JMPQQHXQBO1:/.H(\&3;(D$#M728BJ8NH'U$-0E.X4&8R[=_`I,5;
M$RI'QTRT5*5-DS2O2%$CQF1P)C$*D>XXPHHB!@*;PE$I-.8:"J*.46:S84XZ
M"DE'31N<[Y)V0(MC%D;ET6.^?O`3;MD$M.)A'H#A04\B6:.45BWE=!TX_&MM
MRBL_'(G<KLHZ[IID'*>X9A%R5'K;<AA2$K0BGXMR<O7"40`NH2I?5TCD+Q(N
MZBY,+$4F6Y[&M)'PAI/9AN:.$KV+7>()D!2&Q[&KI`LHHKR@N4H&.`$Y0,%7
M+%L9]!K2UT76Z0EK^NCJS33]`.9C$1Z0F,QM2`$Q2&1A(DJ@E`="F74U.?I"
M@QH]I?M?7O2/MS/-H1/C*Y\='`MPPR8&`+FM4Q^9VU4!(`,#MN01ZM34#%H)
M<VU;B\PVG93*4M>*7S1AU-H<8QB20,K>-J$9#I*PAU7`F?.7\4L(D!JH!A$A
M=2"(4%Z%E[_-O]QO&\)+72G:-R*"0BD'<`IM';=8P!JBH!U"FZPIQY=.7I"@
MNPB<A6G,H)N(^X8EPDJ7G(;PY!,3ETUY@*=0HB'+0)#(-IQR1UG5P11")%$Q
M_P"VH',4H!J)N4BIAY>^/106/YQ[37:QA(",)C(L5*W,Z6\&CK=B%O#GCIR8
M>4$^5GUY@`##H(:`(CPH+*=Q6;<C9K"S82Y1_5KCF\W47)1MKJRI"7+=S=7E
M.V-*`V5*6$AU2#UB@.%"G*@`B)*#*'M)LZ`M^PUY:!:)E922R4='RR0"5M.Q
MT0B5`).-2-Q0B%GAE2-R_P#$1+G'\*@NOH%`^]0*!K]:@4$!'3Z@^_0->CO=
M_P"_]:@TB?3NZ][A]_7_`&T$-0Z=?.`.X/?TUXZ4$>?7[(`']/>H-=`H%`H%
M`H%`H%`H%!*=^_F+>GZ)W'^1WE=E7?$+!MT&BH1CRE/FI>6-V"?[1FS7^9EB
M#X/N=JU8\0WV_6WXY,^WEU'JG5;'MT.%2J;C7^)%]&F_=RV&_"YSQ7G3WZNN
ME_,:T^F2J</OLGZ$&CB>HQ65B[E`H%`H%`H%`H%!`1T#6@T\_P!KIUZ1\X-:
M"/.&NGV^Y01Y@[X4#4.^'V0H(ZAWZ"&H=_[U!2J\+7DHN0-?MBMTPN-N5/U0
M0B90!&]HAN!A-'*%,H1%"81`PF:N=.;G]`<1*/`*=$@D92!E96QHQA>EA7!S
MN9K%TJN#!Y%W"5UUDFK#/UC*>)I1%4#"HT.!2@N4#)&()M:#5,2F/.1G#WG#
MY+40#P1QZGY6+GI:-540`IVZ;T8E)TW>@W.4/0JJF(80#4!"@T7G(*W.GX[N
MAK(V;A2R&J<U(L'K=%%]D)X@0#QT0>(3`[IM`L52D$&X@!WK@2DY0*7B$]8]
MMM\Z=NLBW4V11N2?:)-H2.!,Q/4?:`@19A;Z28F%--ZIP5>'*4HF4'D_!(`4
M%3CIZZ_<^^`T'5O&2#Q!5JZ236073.DJFH0JB:J2A1(=-0A@$IB&*.@@-!B]
MR[LKN:P9FYLF[6KF5LV0EVX.;AQ:X;^%6A=*S93P@RT?HL16&ES<3%4*(:FX
M:T&`[=,UO//%S.$'%F6+9UW,!5825S)LI-:Z!>M`.1<HN05:BU7!0HB`:"8!
MX@-!2/%-C;KX:<L7&MJ9YO9F%US9(8A)YR=ZPC6[@Q>=^D5X!WATFB8B;D`^
MNO"@OLW5[0MSN-D<=6Y_J#NB^K5O5J]3N6<8<UL.U%&@$%>.?MVJACE8"!N9
M(Y%"G-W:"0;3VQ6U:41'RTB6'N9U'*II,/&T"W?NS.04$Q$_"UA\,<+`J/`!
M,90W309=]O.Q!SE)W"Y5W)F<R3-BS3:VA8O*>+:!$(BF=FX>,VJI09,EB_\`
M)$175*'XPV@Z4&8&-81T/'LHF*9-XZ,CFR+)BQ9I$;M6C5NF":*#=%,"D333
M(4```H.:)^]W_M?7H(<_?^MIPU\^@=8`::_7X_TCQH("IQTU`/,`=!^STT$!
M4T#3AT^>(<?O4$.?NZ\!'3[/^R@T\X``CK][A]>@=8'0&OWA^S00YR]_7CIP
M^K2@=8&O=^_]V@B4_H@#CQ,'V!$*#E4"@4"@4"@4"@4"@4$IW[^8MZ?HG<?Y
M'>5V5=\0L&W0:*A&/*4^:EY8W8)_M&;-?YF6(/@^YVK5CQ#?;];?CDS[>74>
MJ=5L>W0X5*IN-?XD7T:;]W+8;\+G/%>=/?JZZ7\QK3Z9*IP^^R?H0:.)ZC%9
M6+N4"@4"@4"@4"@4&D_X(_6^[0;-`H%!'A]7^^@U`.NFH:Z:`&GG]WCTT#@`
MZB/1W.`B/V^X-`T#777AT]&O'4.`Z>?04WE[`4+-&N>S)HUH3;IPFI-II,TW
MT)<J:9>K_P#&(HRB)?#"ICH5RD8BP:!S"8.%!$BF7!=E;J)6"1CS`!I$KF;,
M\$G-^&6/%N5#G$O'3K=-:#A?JR&;F&\W?\ZXN\T7)MY2!@O!RQELP;QH`@V=
M$C$#J'DWJ9C<X*.CJ@4X:E*4:"K`@!@^_0;!R!W>/>&@V#)]WI\WH'['=H.(
MJU(H`E.74#=/_".O<'IZ:#'ON3V5PF0)I3)=BE;0]\I('/)11T4DX.\^J`3)
MIR)N41CY0=-".2@)1'3G#NT&&]E`3&'=R&+K/R!`R-O2TM>SAZLI,)/'8HN7
M:A/%@1<J<IHTK=;7JQZDX%.``/+K09,]_P!(6[;]BVJUN"0>MG<Z=*&MF&C2
MNE9F?D'IB'7;LDF1%7R;=%(!%98I>!>`#J-!47:=M,*6+M;).5HE5.7:@$A;
M=H/Q,HA&I"0I(^3E&RGH0?BW*!BIF#F)J`F'6@R::%*4I"Z<H`'1H`!H&@``
M!P``"@TT#C]O[6O]%!#_`&=V@AQ'7O"`:='UZ"`CIP$H:\--//Z`[H#0:3>:
M`AT<O1]?7NT&C[=`H%`_I\S[]!#[_P#0-!J*`"<H<?PB^</HONZT'/H%`H%`
MH%`H%`H%`H)3OW\Q;T_1.X_R.\KLJ[XA8-N@T5",>4I\U+RQNP3_`&C-FO\`
M,RQ!\'W.U:L>(;[?K;\<F?;RZCU3JMCVZ'"I5-QK_$B^C3?NY;#?A<YXKSI[
M]772_F-:?3)5.'WV3]"#1Q/48K*Q=R@4"@4"@4"@4"@VU1T+TZ<0^[W>(<*#
MC@</-[FO#[/=H-7,'3J&G'3O\/,H`&`>Z'<^MYGFC0.8.@!U'ZO."@CS!W]/
M,$>CSP[]`U#73S-?K4$=>CB/F<>Y0*!KIW1Z/Z-:!KW-?.#6@U`80[H_7U[O
M1PU"@U<Y1#0=1Z.CH^[W!H("!1Z!T\_H'^B@T"4!XZ:]S77[O>H-LR11U*8.
M`](#Q^UW0&@DF\<;65?\4M"7C;D5<,8L)3=3(M$EE6ZJ9@.DNQ="7PIBX04`
M#$.D<ABCT#02];6#,96O+)3[.VT)">;HIMVDU<"[BX9)BW2#1-&.<RIW/@!0
M#NI`0P]T:"K0G`O1K]8>]]C2@T\X::_8#N_7Z:"`G[WV^C[`4$.;0>`CIYO'
M_=0.;IU$>CAIPX]\:"`&$/-'S1'^GC00YAX<>CH^O]V@AKKYH<>.O1_OH(";
M0..O3I]C[U!`1'30!Z==`[_FAQZ=*#1S:!Q'4?/Z-->D0X#00YA^WKK]70%!
M`1$>[0:B"/.7B/X1>Z/?"@[6@4"@4"@4"@4"@4"@E._?S%O3]$[C_([RNRKO
MB%@VZ#14(QY2GS4O+&[!/]HS9K_,RQ!\'W.U:L>(;[?K;\<F?;RZCU3JMCVZ
M'"I5-QK_`!(OHTW[N6PWX7.>*\Z>_5UTOYC6GTR53A]]D_0@T<3U&*RL7<H%
M`H%`H%`H%`H..Z$2I"(`8>)?P0$P]/3H4!&@ZP%C@.@I+<1T_JCCQ\WAP"@W
M`4.("($4T#775,P"&@=P.7C00ZT_#\4KT:_U1^[IIW.[0:NL/Q_%*\-`X)GZ
M1T'[``-!#G./#JU0_P#9'^[H-!JYSB.G5*!IIQ%,VG'O4$0.<1_JS^:/(</L
M`(=-`ZPW_9JZ<-/Q9_Z!Z*`!CC_P'^N0X?=`*"'6'[J:G=T'JS_6TX#IQH(]
M88>A-7ZZ1PT\\.6@=8<!Y134T'O)F'O:\0#N4$>L.`"($5U#30.K/T><(4$.
MN4T_JU.'#@F<=>_PY=0$*"(K*:\"*:#WTC\.'=X?<H(=<H8`$"*!_P"S4`/L
M::_=H(=8H/#JU--1XBFII]C37C0:.M.(?U2W'_U)]0#['100ZT^@Z)+#Q_[(
M_'[0Z!0.M/IKU:WG`D;[Y0Z`H-/7GTU!-<>(!_4F^SQ+00%<^FO5+Z:Z<$C]
MWS@_W4$>N/IQ27``Z!ZHXB.O'CH%!I%<X#H"2_G]6?[P#0:17.&A>I6$-1#@
MDIIIW!'T(4$.O4$1#J%]`Z-4E./VN%!H\(4TU\'<<1'_`)"@B&G?]#]Z@@=9
M370$%]=.D$5>7NCI^#II0;0N5AU_LSG7S$%=.'<_!Z0H-/A*PAQ;N>CA^(5$
M-->D?0T&XDLMUJ("@OH*J8&$45`TU.&IM1*`:``\:"9Z!0*!0*!0*!0*!0*"
M4[]_,6]/T3N/\CO*[*N^(6#;H-%0C'E*?-2\L;L$_P!HS9K_`#,L0?!]SM6K
M'B&^WZV_')GV\NH]4ZK8]NAPJ53<:_Q(OHTW[N6PWX7.>*\Z>_5UTOYC6GTR
M53A]]D_0@T<3U&*RL7<H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!*=^_F+>GZ)W'^1WE=E7?$+!
MMT&BH1CRE/FI>6-V"?[1FS7^9EB#X/N=JU8\0WV_6WXY,^WEU'JG5;'MT.%2
MZZ]LVV5MKW8]@!N"R1XX]0&%]F&S?)EY^I]@25G/4W9VZ'<'.2_BF-4<LDWT
MAX$S/U20K)@<^@<P=-=%5U%/?V?^EW0/Z]5F,XPG:YK&PV/'TTPPX^R5?*00
MXZFBBFFBCRTT>6GR4_X_X?$=EAL,S*V6/*0V."FG_P`1Q/KW\KE[)CTNY[VF
M8KU_5^.KSZZ]S7;$>\K!Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(
M9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2
M\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7
MLF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'
MO)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9
MBO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`H
MQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO
M<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2
M[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_
M(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]
M2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN
M7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ
M'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:
M9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`
MHQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^N
MO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/
M2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q
M_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7
M]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3R
MN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UV
MQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO
M:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O
M`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^
MNO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF
M/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)
MQ_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO
M7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3
MRN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<U
MVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[G
MO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9
MO`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\
M^NO<UVQ'O)Q_(9O`HQ3RN7LF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ3RN7L
MF/2[GO:9BO7]2\^NO<UVQ'O)Q_(9O`HQ71W1]+3[)^8MJXHAJ&YP',I!2\<W
M%3#444@+O8]PV1YS>KWT)>L5#4>X%=$IX0KKEAFK%9H^+,;!9(::?_O'_JBF
MBG67Q%7\A3#31D_]?]48KY->P3_:-V:_S,L0?!]SM7ZU\0]'D_K];_CDS[>7
M>#5.JV/;J,*E025_U7?JNVS_`*VO]*GJ3_T]VO\`Z;O]1W^@?U>?Z<_5;?/J
M1\!_6/\`];>ICU7^/O!O&/\`:.NZ_7AI5IENIG&59<2\;?RN,(_YG\/C;U7\
MOU=BQ_E]3_\`+'^J]3CL9_CR8U]%/\C&0>L]7C<9D<=ZORXWRT^3_?\`GR>7
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MNFS)[#N;(9V7'ZWO_,*[/;U0_J$_5)_K(MW3_3C_`*3O%/ZT_P!6U\>)?5M^
MH#_QOK_4GXQ\"\._L_)U_5_C-:_F-UOB+_\`/*__`(W&''7%%D]\XPQWJ<?!
GC_5_R\CY,?C,=C?\^7&>7_#MD/6_R[%CL9ZOUE&5QG^_)_SC7__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
